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The latent reservoir (LR) for HIV-1 in resting memory CD4+ T-cells harbors integrated, 
replication-competent proviruses that are not actively transcribed while the T-cell remains 
in a resting state.  Recent work has shown that proliferation of infected cells is a major 
factor in the generation, persistence, and stability of the latent reservoir.  Given that the 
latent reservoir is the major barrier to HIV-1 cure, it is important to understand the 
proliferative process that contributes to the persistence of the LR. Stimuli that drive T-cell 
proliferation can also reactivate latent HIV-1, but productively infected cells have a short 
half-life.  Several groups have shown that latently infected cells that clonally expand in 
vivo can be reactivated in vitro without producing virus. One hypothesis to explain this 
observation is that certain latently infected memory CD4+ subsets may be in a deeper state 
of latency and therefore may be able to proliferate without producing virus.  
 To evaluate this possibility, we cultured resting naïve (TN), central memory (TCM), 
transitional memory (TTM), and effector memory (TEM) CD4+ T-cells from 10 HIV 
patients on suppressive ART in a multiple stimulation viral outgrowth assay (MSVOA). 
The frequencies of viral outgrowth calculated from p24 ELISAs were compared to the 
frequencies of intact proviral DNA copies calculated by the droplet digital PCR-based 
Intact Proviral DNA Assay (IPDA), and on average, only 1.5% of intact proviruses across 
all subsets were induced by multiple rounds of global T-cell activation. In addition, there 
was no enrichment of intact proviruses in any specific subset nor any correlation between 
the inducibility of intact proviruses and memory subset phenotype. Furthermore, we 
observed significant plasticity among the canonical memory subset surface markers during 
culture of the cells and saw significant patient-to-patient variability in inducibility patterns 
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that complicates the vision for a targeted cure approach based on T-cell subsets. 
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There are 37 million people in the world infected with HIV-1, of whom 15.8 million are 
effectively receiving antiretroviral therapy (ART), which prevents new infection events 
and reduces viral copies to undetectable levels10. However, ART is not curative in that the 
virus can establish latency by integrating into the host genomes of activated CD4+ T cells 
as a provirus1. Reversion of these activated CD4+ T cells into resting memory CD4+ T 
cells allows the virus to evade transcriptional expression, immune clearance, and ART, 
thus forming the HIV-1 latent reservoir (LR)11. The long half-life of the LR implicates that 
it would take more than a patient’s lifetime of ART to cure HIV12. Thus, elimination of the 
persistent latent reservoir is the key approach to HIV cure.  
 Although the reservoir consists mostly of defective virus, about 2% of it contains 
intact virus13. The standard viral outgrowth assay (VOA) was developed to measure the 
frequency of latently infected cells containing replication-competent virus by culturing 
resting memory patient CD4+ T cells after dilution at a Poisson distribution such that only 
one virus is present in each culture well, and then activating these cells to proliferate and 
induce viral replication14,15. Previous studies have shown that the standard VOA is a 
minimal estimate of the size of the LR as additional virus has been shown to grow out after 
repeated stimulation2. This additional virus was previously thought to be intact but 
noninducible virus. In one of the studies presented in this work, resting CD4+ T cells of 
chronically infected HIV patients were repeatedly activated in a multiple stimulation VOA 
(MSVOA) to induce latent virus to replicate. After observing additional induced viruses 
after multiple stimulations, we sequenced the viral RNA and found identical sequences 
from different wells. These findings suggested that the replication competent viruses arose 
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from in vivo clonal expansion of latently infected cells containing replication-competent 
virus as multiple identical clones were found in each patient from a single blood draw. This 
implies that the LR persists by clonal expansion of these resting memory cells containing 
replication-competent virus. There are two possible mechanisms for clonal expansion: 1) 
one virus infects multiple precursor memory cells which then proliferate, or 2) one virus 
establishes latency in one precursor memory cell which then proliferates. The latter is most 
likely given the identical sequences among clones and the large number of clones sampled 
in a single blood draw from a patient. The lack of mutations between the sequences 
suggests expansion by cellular proliferation rather than viral replication followed by 
cellular proliferation. The specifics of the mechanism of clonal expansion are unknown. 
From this study, we concluded that intact, replication-competent proviruses persist through 
in vivo clonal expansion of these infected cells that can be activated without producing 
virus.  
 Several groups have now shown that latently infected cells that clonally expand in 
vivo can be activated in vitro without producing virus. One hypothesis to explain this 
observation is that certain subpopulations of reservoir cells, such as particular CD4+ 
memory subsets, are predisposed to delay reactivation of the latent virus or promote a 
deeper state of latency. To evaluate this possibility, we cultured resting naïve (TN), central 
memory (TCM), transitional memory (TTM), and effector memory (TEM) CD4+ T-cells 
from 10 HIV patients on suppressive ART in the MSVOA. The frequencies of viral 
outgrowth calculated from p24 ELISAs were compared to the frequencies of intact proviral 
DNA copies calculated by the droplet digital PCR-based Intact Proviral DNA Assay 
(IPDA), allowing us to estimate that on average only 1.5% of intact proviruses can be 
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induced by multiple rounds of global T-cell activation. There was no enrichment of intact 
proviruses in any specific subset nor any correlation between the inducibility of intact 
proviruses and memory subset phenotype. Furthermore, we observed significant plasticity 
among the canonical memory subset surface markers and saw significant patient-to-patient 
variability that complicates the vision for a targeted cure approach based on T-cell subsets. 
 Overall, we have concluded that the LR persists through clonal expansion of 
infected cells, among other mechanisms. We have determined that replication-competent 
proviruses in these clonally expanded cells can be reactivated without producing virus, thus 
contributing to the persistence of the latent reservoir. Lastly, we have determined that the 
differential inducibility of these replication-competent proviruses is not related to the 
memory subset phenotype of the cell they are harbored in, and of these cells that contain 
intact proviruses, only a small fraction can be induced to replicate in culture. Next steps 
for the field would include investigation of these noninduced intact proviruses to determine 
whether they actually can be induced to replicate and what role they play in residual 




CHAPTER 1: The Latent Reservoir for HIV-1: How Immunologic 
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Combination antiretroviral therapy (ART) for HIV-1 infection reduces plasma virus levels 
to below the limit of detection of clinical assays.  However, even with prolonged 
suppression of viral replication with ART, viremia rebounds rapidly after treatment 
interruption; thus ART is not curative. The principal barrier to cure is a remarkably stable 
reservoir of latent HIV-1 in resting memory CD4+ T cells. Here we consider explanations 
for the remarkable stability of the latent reservoir.  Stability does not appear to reflect 
replenishment from new infection events but rather normal physiologic processes that 
provide for immunologic memory. Of particular importance are proliferative processes that 
drive clonal expansion of infected cells.  Recent evidence suggests that in some infected 
cells, proliferation is a consequence of proviral integration into host genes associated with 
cell growth.  Efforts to cure HIV-1 infection by targeting the latent reservoir may need to 





In 2014, ~37 million people were living with HIV-1 infection (www.unaids.org). Optimal 
patient outcomes are achieved by initiating combination antiretroviral therapy (ART) as 
soon infection is diagnosed, regardless of the CD4+ T cell count (1-3).  ART reduces 
plasma virus levels to below the clinical detection limit (20-50 copies of HIV-1 RNA/ml) 
and halts disease progression (4-6).  Recommended initial regimens consist of two 
nucleoside analog reverse transcriptase inhibitors and a third drug, either an integrase 
inhibitor or the protease inhibitor darunavir (3). Although ART effectively suppresses 
viremia, it is not curative, and viremia rebounds upon ART cessation (7, 8).  Therefore, 
lifelong treatment is required.  Providing lifelong treatment for all infected individuals 
poses a major economic and logistical challenge. Only 15 million people currently receive 
ART.  The tolerability of ART regimens has improved dramatically, but long term drug 
toxicity is also a concern.  Other problems include the emergence of resistance with 
suboptimal treatment and the stigma associated with the infection.  For these reasons, there 
is great current interest in a cure (9, 10).    
The principal barrier to cure is a stable reservoir of latent HIV-1 in resting CD4+ T 
cells (11, 12). The reservoir persists even in patients on long term ART who have no 
detectable viremia (13-18).  The cells comprising this reservoir have a memory phenotype 
(12, 19-23).  Direct measurements of the latent reservoir in patients on ART show a very 
slow decay rate (t1/2=3.7 years) (16, 17).  At this rate, eradication of a reservoir of 10
6 cells 
would require 73 years, making cure unlikely even with lifelong ART.  Thus, research 
towards a cure focuses on eliminating this reservoir.  Recent reviews have discussed 
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molecular mechanisms of HIV-1 latency (24-27) and approaches for eliminating the 
reservoir (10, 28-30).  Here we consider explanations for its remarkable stability.   
 
Why does HIV-1 establish latent infection?  
Viral latency is a reversibly nonproductive state of infection of individual cells (31).  
Latently infected cells contain a stable form of the viral genome, either as a circular plasmid 
in the case of herpesviruses or as a linear provirus stably integrated into host cell DNA in 
the case of HIV-1.  During latency, there is highly restricted expression of viral genes (31).  
For some herpesviruses, latency evolved as an essential mechanism of immune evasion 
and viral persistence (31, 32).  For HIV-1, latency is not necessary for persistence as active 
viral replication occurs throughout the course of infection in untreated patients (33).  
Escape from immune responses is through rapid evolution of variants not recognized by 
cytolytic T lymphocytes (CTL) or neutralizing antibodies (34-41).  Nevertheless, a latent 
reservoir is established rapidly in all HIV-1-infected individuals (42).  Latently infected 
cells can be detected in the rare individuals who spontaneously control HIV-1 infection 
without ART (43).  Early ART restricts the size of the reservoir (22, 44) but does not block 
its establishment (42).  In rhesus macaques infected with simian immunodeficiency virus 
(SIV), which also establishes a latent reservoir in resting CD4+ T cells (45, 46), initiation 
of ART on day 3 post infection prevents detectable viremia but not the establishment of a 
latent reservoir (47).  Thus, it is difficult to prevent the establishment of the latent reservoir. 
A recent theory suggests that HIV-1 evolved a mechanism for rapid establishment 
of latent infection to facilitate transmission across mucosal barriers (48, 49).  Latency is 
proposed to serve as a “bet-hedging strategy” that allows some infected cells to survive 
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long enough to transit the mucosa. However, as is discussed below, infected cells can 
remain in a latent state for years, and a long time interval between mucosal exposure and 
viremia has never been documented. 
Latency is most simply explained as a consequence of viral tropism for activated 
CD4+ T cells which can transition to a resting memory state that is non-permissive for 
replication (Fig. 1).  HIV-1 has a strong propensity to infect activated CD4+ T cells (50, 
51). CCR5, a critical co-receptor for entry of the commonly transmitted forms of HIV-1 
(52-57), is upregulated on CD4+ T cell activation (58). Following entry, reverse 
transcription of the viral RNA genome into DNA and integration of the resulting provirus 
into host cell DNA occur within hours (59).  Transcription of the integrated provirus then 
begins because active nuclear forms of key host factors needed for the initiation and 
elongation of viral transcription, including NFκB, NFAT, and pTEFb, are present in 
activated cells (60-67).  In contrast, resting CD4+ T cells mostly lack CCR5 expression 
(58), and other factors interfere with HIV-1 replication even when the virus has 
successfully entered.  The cellular protein SAMHD1, a deoxynucleoside triphosphate 
triphosphohydrolase, depletes dNTP levels, thus impeding reverse transcription (68-70).  It 
is expressed at high levels in myeloid cells and resting CD4+ T cells (52-55).  Interestingly, 
SIV and HIV-2 encodes a protein, Vpx, that promotes SAMHD1 degradation (68, 71).  
However, HIV-1 lacks Vpx, and thus reverse transcription in resting CD4+ T cells is 
inefficient, taking as long as 3 days (72-74).  The static nature of the actin cytoskeleton in 
resting cells inhibits delivery of the reverse transcribed viral genome to the nucleus (75).  
These delays facilitate recognition of DNA intermediates generated during reverse 
transcription by a host innate DNA sensor, IFI16, leading to caspase-1 activation and a 
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proinflammatory form of cell death known as pyroptosis (76-78).   Additional barriers to 
replication in resting CD4+ T cells include the lack of active forms of NFκB, NFAT, and 
pTEFb needed for transcription of the provirus (60-63, 65, 66). 
Although activated CD4+ T cells are the principle target for HIV-1, they die quickly 
after infection. Classic studies of viral dynamics revealed a rapid decay in viremia when 
new infection events are blocked with ART (6, 79-81).  This decay reflects the short half-
life of plasma virions (t1/2 ~ minutes) and of the infected cells that produce most of the 
plasma virus (t1/2 ~ 1 day). Activated T cells are prone to die in the contraction phase of 
immune responses due to activation-induced cell death (82).  In addition, productively 
infected cells may die from other cell death pathways triggered by viral proteins or by 
integration of the provirus into the host cell genome (83, 84).  Infected CD4+ T 
lymphoblasts may also be lysed by CD8+ CTL (34, 85-87).  Surprisingly CTL do not appear 
to shorten the t1/2 of productively infected cells (88, 89).  Nevertheless, it appears that most 
productively infected CD4+ T lymphoblasts are short-lived.  
Given that resting CD4+ T cells are resistant to infection and that activated CD4+ T 
cells die quickly after infection, how is the latent reservoir established?  Some infected 
CD4+ T lymphoblasts may survive long enough to revert to a resting memory state that is 
non-permissive for viral gene expression (11), particularly if they are infected within a 
narrow time window when still permissive for steps in the life cycle up through integration, 
but not for high level gene expression (Fig. 1).  Thus, establishment of latent infection is a 
rare event, consistent with the low frequency of latently infected cells in vivo (1/106) (13, 
16-18).  Latency may be further enforced by silencing epigenetic modifications of the 
integrated provirus (90-92).  In this latent state, the virus persists essentially as genetic 
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information. When antigen or cytokines subsequently activate the cell, the provirus is 
transcribed, viral proteins are produced, and virus particles are released.  Given the long 
t1/2 of memory T cell responses and the fact that the latent proviruses in these cells are not 
detected by the immune system or targeted by ART, stable persistence of HIV-1 is not 
surprising.  This simple model views latency in the context of the normal physiology of 
immunologic memory, thereby explaining all clinical observations regarding HIV-1 
persistence without requiring the evolution of special viral mechanisms for latency. 
 
Residual viremia, the latent reservoir, and viral rebound 
Trace levels of free virus (~1 copy/ml) are present in the plasma of most patients on ART 
(93-95).  Sequence analysis of the residual viremia (RV) reveals that these viruses resemble 
viremia present earlier in infection, are sensitive to the patient’s current ART regimen, and 
generally do not show evidence of ongoing evolution (96-100).  These features all suggest 
RV originates from a stable reservoir (101).  In situations where evolution has been 
detected, suboptimal ART may be the cause (102).  Importantly, intensification of standard 
three drug ART with additional antiretroviral drugs from a different class does not reduce 
RV (103-105), indicating that it originates from long-lived cells infected prior to ART.  
Latently infected resting CD4+ T cells are at least one source of RV.  The presence of RV 
suggests that multiple latently infected cells are become activated every day. While patients 
remain on ART, the viruses released do not infect additional cells.  However, if ART is 
interrupted, viral rebound occurs.  Rebound is typically seen within 2 weeks (7, 8), the time 
required for washout of antiretroviral drugs and growth of the recently released viruses to 
detectable levels.  The rebound virus is archival in character, consistent with the conclusion 
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that it originates from a stable latent reservoir (106).  The limited variation in time to 
rebound, despite a two log variation in reservoir size, also suggests that multiple cells are 
activated per day (107).  This conclusion is consistent with a recent analysis of viral 
rebound which detected multiple viral lineages emerging in multiple sites (lymph node, 
ileum, and rectum) (8).   
 
Evidence for latent infection of resting memory CD4+ T cells. 
This model for latent HIV-1 infection as a barrier to cure is supported by several lines of 
evidence:  1) Replication-competent HIV-1 can be readily recovered from highly purified 
resting CD4+ T cells from essentially all infected individuals, regardless of the duration 
of ART (12, 13, 15, 16, 18, 108).  Recovery requires activating the cells to reverse 
latency, as predicted by the model.  As is discussed below, recovery only fails when the 
size of the latent reservoir is substantially reduced (44, 109-111).  Controversy remains 
over the question of whether other cell types including macrophages serve as stable HIV-
1 reservoirs (112-123).  To date, long term persistence of replication-competent HIV-1 in 
the setting of optimal ART has only been demonstrated for resting CD4+ T cells (124).  
This may in part reflect the difficulty of sampling tissue macrophages, particularly in 
sites such as the central nervous system.  Persistence in tissue macrophages can in 
principle be studied in novel humanized mouse models (123) and in the SIV model, but 
only through the use of animals on fully suppressive, long term ART and with the caveat 
that restriction by SAMHD1 is counteracted by SIV Vpx (68, 69).  2) Latent HIV-1 is 
found in resting memory CD4+ T cells but only to a limited extent in naïve CD4+ T cells 
(12, 19-23).  3) The generation of latently infected cells can be reproduced in vitro in 
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primary CD4+ T cells that have been activated in some manner, infected, and then 
cultured to allow reversion to a resting state (125-129).  Restimulation of these cells 
through the T cell receptor (TCR) leads to HIV-1 gene expression.   Together, these 
results support persistence of latent HIV-1 in resting CD4+ T cells that have been 
previously infected while in an activated state. 
The general concept of HIV-1 latency is also strongly supported by the cure and 
“near cure” cases of the “Berlin patient” (109), the two “Boston patients” (110, 111), and 
the “Mississippi baby” (44).  The Boston and Berlin patients were HIV-1-infected 
individuals who developed malignancies requiring hematopoietic stem cell transplantation 
(HSCT) resulting in immune reconstitution with donor cells.  The Berlin patient received 
HSCT from a donor whose cells were homozygous for a deletion in CCR5 and was cured 
as the reconstituting T cells were not permissive for entry of R5-tropic HIV-1 (109).  
Attempts to reproduce this cure have thus far been unsuccessful due in large part to 
progression of the malignancy.  In one case, the appearance of viral variants that utilize the 
alternative HIV-1 coreceptor, CXCR4, has been noted (130).  The Boston patients received 
HSCT from donors with wild-type CCR5, and ART was continued throughout the 
transplant period to protect donor cells from infection.  When apparently complete 
reconstitution with donor T cells had occurred, and HIV-1 was no longer detectable by 
standard assays, ART was interrupted.  The patients maintained suppression of viremia for 
3 and 8 months before sudden and dramatic rebounds. 
The Mississippi baby, born to an infected mother who had no prenatal care, had a 
plasma HIV-1 RNA level of ~20,000 copies/ml shortly after birth and was immediately 
started on ART.  Plasma HIV-1 RNA declined to below the limit of detection and remained 
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there even after treatment was interrupted against medical advice between 15 and 18 
months of age.  Treatment was not restarted, and viremia remained undetectable for over 
2 years before suddenly rebounding.  Importantly, HIV-1-specific T cell responses were 
absent in all three subjects because of the transplant process or early treatment.  Antibodies 
to HIV-1 were not detected in the Mississippi baby and were markedly decreased in the 
Boston patients.  Because HIV-1 replication is exponential in the absence of immune 
responses and ART, HIV-1 persistence for months or years in these patients can be best 
explained by the non-replicating or latent form of the virus.    In these cases, HSCT or early 
ART delayed rebound by reducing the number of latently infected cells to the point where 
stochastic reactivation was a rare event (107). 
 
Explanations for the long t1/2 of the latent reservoir  
The decay rate of the latent reservoir was originally measured using a viral outgrowth 
assay (VOA), which quantifies viral outgrowth from limiting dilutions of mitogen-
stimulated resting CD4+ T cells from patients on ART (13, 131-133).  The original VOA-
based measurements of the reservoir decay, published in 1999 and 2003, indicated a t1/2 
of 3.7 years (16, 17).  This value was confirmed in a more recent study (t1/2 =3.6 years), 
indicating that despite the development of newer, less toxic, and more convenient ART 
regimens, the fundamental problem of the reservoir as a barrier to cure has not been 
overcome (18).  A critical issue is whether the remarkable stability of the reservoir is the 




One controversial explanation for stability is that the reservoir is constantly 
replenished by a low level of de novo infection that continues despite ART (134).  This 
replication may reflect inadequate drug levels in certain anatomical sites including the 
lymph nodes (135, 136) or cell-to-cell spread which is more difficult to block with ART 
(137).  However, multiple lines of evidence indicate that ART effectively curtails new 
infection of susceptible cells.  Because HIV-1 replication is invariably accompanied by the 
progressive accumulation of mutations (138) reflecting the error prone nature of reverse 
transcriptase (139) and possibly hypermutation by the host restriction factor APOBEC3G 
(40, 140-143), the lack of sequence evolution in the viral reservoir (22, 97, 100, 144, 145) 
indicates that ART blocks ongoing cycles of viral replication.  A recent report claiming 
evolution is confounded by sampling only in the first 6 months of ART, a period during 
short-lived populations of infected cells not representative of the stable reservoir are 
dominant (146).  Prior to the development of effective ART, a dominant clinical issue was 
the evolution of drug resistance (147-151), but the incidence of resistance is now 
decreasing (152-154).  Indeed, there are overwhelming clinical data that ART is effective, 
and treated patients can expect a near normal life expectancy (3, 155-158).  As mentioned 
above, the failure of ART intensification to reduce RV indicates that current ART regimens 
stop new infection events (103-105).  Finally, in the delayed rebound cases mentioned 
above, HIV-1 persistence during ART cannot be explained by ongoing replication as this 
would have led to immediate rebound.  Therefore, the stability of the latent reservoir is 
most likely due to the long t1/2 of memory T cells and their renewal through proliferation. 
Functional studies have shown that memory CD4+ T cell responses in humans can 
provide lifelong immunity.  In individuals who received the smallpox vaccine or cleared 
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Hepatitis C infection, virus-specific CD4+ T cell responses persist for decades despite the 
absence of further antigen exposure (159, 160).  Early studies of the memory cell lifespan 
in humans examined radiation-induced chromosomal abnormalities that preclude cell 
proliferation.  This allowed estimates of the intermitotic t1/2 of lymphocytes (161, 162).  
The measured t1/2 of 22 weeks for memory T cells is roughly consistent with subsequent in 
vivo measurements using glucose or deuterium labeling which indicate a t1/2 on the order 
of months for human memory CD4+ T cells (163, 164; also reviewed in 165).  This is 
substantially shorter than the t1/2 of individual naïve T cells (1-8 years). Importantly, it is 
shorter than the t1/2 of the HIV-1 reservoir (3.7 years) and of functional memory T cell 
responses (8-12 years). The discrepancy between the half-life of individual memory T cells 
and the overall memory immune response suggests that proliferation of memory cells must 
contribute to the stability of the latent reservoir.  However, as discussed above, 
productively infected cells have a very short t1/2, and therefore the concept that infected 
cells can proliferate is not well appreciated.  The HIV-1 Vpr protein induces cell cycle 
arrest at G2 by interacting with a host E3 ubiquitin ligase (166, 167) and stimulating the 
degradation of host proteins including the DNA replication factor MCM10 (168).  For cells 
in a latent state of infection, this block to proliferation is not operative, and latently infected 
cells can, in principle, proliferate if the driving stimulus does not strongly upregulate HIV-
1 gene expression (169-172). 
Memory CD4+ T cell proliferation can be driven by antigen, cross-reactive 
recognition of other self or foreign peptides presented with MHC class II, or cytokines.    In 
the murine system, neither antigen nor class II MHC is required for memory T cell 
persistence (173), although memory CD4+ T cells that persist in the absence of MHC class 
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II are functionally impaired (174).  The requirements for maintenance of human memory 
CD4+ T cell responses is less clear and could include interactions with cognate signals or 
cytokines.  Little is currently known about the antigen specificity of cells harboring latent 
HIV-1, although a small subset of them may be HIV-1-specific (175).   However, human 
memory CD4+ T cells exhibit cross-reactivity, and specificities for antigens never 
encountered can be detected among memory CD4+ T cells in peripheral blood (176).  As 
discussed above, it is expected that stimuli acting through the TCR will upregulate 
expression of latent HIV-1, but this may not be the case for cytokine-driven proliferation.  
The cytokines implicated in memory T cell homeostasis and survival are IL-7 and IL-15 
(reviewed in 177). IL-7 is required for stimulating homeostatic proliferation of memory 
CD4+ T cells.  Mice deficient in IL-7 (or IL-7R) have severely reduced total T lymphocyte 
levels and reduced splenic size and cellularity (178). IL-15 also plays a role in homeostatic 
proliferation of memory CD4+ T cells (179).  Early in vitro studies indicated that IL-7 can 
actually induce expression of latent HIV-1 (180, 181).  However, in patients on ART, 
infusion of IL-7 leads to the proliferation of memory CD4+ T cells, including latently 
infected cells, with little or no induction of HIV-1 gene expression (182, 183).   In vitro 
studies in a primary cell model of HIV-1 latency confirm that latently infected cells can 
proliferate in response to IL-7 (plus IL-2) without upregulation of HIV-1 gene expression 
(169).  These studies suggest that the latent reservoir can be maintained within memory T 
cells undergoing homeostatic turnover.   Analysis of memory T cell subsets has provided 
additional insight into this issue. 
 
Memory CD4+ T cell subsets 
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 Memory T cells can be divided into two main subsets, central memory (TCM) and 
effector memory cells (TEM), based on expression of homing and chemokine receptors 
involved in preferential trafficking to secondary lymphoid organs or peripheral sites, 
respectively (184).  HIV-1 DNA is preferentially harbored in TCM and another subset of 
memory T cells, transitional memory T cells (TTM) (21). TTM have a phenotype 
(CD45RA-, CD27+, CCR7-) intermediate between TCM and TEM. The two main subsets of 
CD4+ memory T cells that harbor latent HIV-1, TCM and TTM, may provide a more stable 
reservoir for HIV-1 than TEM cells, which have a higher proliferative index and are more 
susceptible to programmed cell death (21, 185).  A recent study using the viral outgrowth 
assay rather than PCR demonstrated replication-competent HIV-1 persisting in TCM but 
to a much lesser extent in TTM, indicating that TCM may represent the major source of 
persistent HIV-1 in most patients (186). 
Another recently defined subset of memory CD4+ T cells that may contribute to HIV-1 
persistence is the stem cell-like memory T cell subset (TSCM) (187).  TSCM are 
phenotypically similar to naïve T cells (TN) in that they are CD45RO
-, CD45RA+, and 
CCR7+.  However, they also express surface markers characteristic of memory cells, such 
as CD95 and IL-2Rβ (187).  TSCM rapidly respond to antigen and secrete IFN-γ, IL-2, and 
TNF.  They are also stimulated to proliferate by IL-7.  A stepwise progression from TN to 
TSCM to TCM to TEM has been proposed, with TSCM potentially able to give rise to other types 
of memory T cells and self-renew upon stimulation. TSCM can be infected with HIV-1 in 
vitro, and in patients on ART, HIV-1 DNA is present in TSCM at higher levels than in other 
memory subsets (188).  Although latently infected TSCM represent only a small fraction of  
the total reservoir, they may be of particular importance because of their stability and 
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capacity for self-renewal (23, 188).   
In summary, analysis of memory subsets reveals HIV-1 genomes distributed in 
multiple memory cell subsets, with higher frequencies in subsets with greater potential to 
survive.  Several issues remain.  One concern is that many studies of the distribution of 
HIV-1 genomes in T cell subsets rely primarily on PCR-based measures of the proviral 
DNA.  This is problematic in that the vast majority of proviruses in resting CD4+ T cells 
from treated patients are highly defective (189).  There is also substantial patient-to-patient 
variability in the distribution of viral genomes within these subsets.  Finally, these subsets 
are not static and can interconvert in ways that are not yet fully understood, and it is 
therefore unclear whether latent HIV-1 stably persists in a given subset.   
 
Anatomical distribution of the latent reservoir 
Most studies of the latent reservoir sample CD4+ T cells from peripheral blood.  
Given the continuous recirculation and wide tissue distribution of memory T cells, it is 
generally presumed that latently infected resting CD4+ T cells will be present in most 
secondary lymphoid organs and in non–lymphoid tissues (190-192).  Early studies 
demonstrated latently infected cells at roughly equal frequency in blood and lymph nodes 
(12).  In the SIV model, latently infected resting CD4+ T cells were demonstrated in blood, 
lymph node, and spleen (45, 46).  Interestingly, as is discussed below, some recently 
described memory cell populations that are not present in the blood may also contribute to 
HIV-1 persistence. 
HIV-1 can infect follicular helper T cells (TFH) (193-196), and this population has 
received considerable attention because CD8+ CTL lack chemokine receptors needed for 
18 
 
migrating into B cell follicles (196), thus making the follicles a site of “immune privilege”.  
In the subset of rhesus macaques that spontaneously control SIV, viral replication is 
restricted to TFH, presumably because CD8
+ CTL lyse infected cells elsewhere in the node 
(196).  The extent to which TFH serve as a long term reservoir for HIV-1 in the setting of 
optimal ART remains to be determined.  If latently infected TFH persist, HIV-1 eradication 
strategies may need to include not only latency reversing agents and stimuli to enhance the 
CD8+ CTL response (197), but also interventions to disrupt B cell follicles to permit access 
by CTL (196). 
  Another population of memory T cells that could potentially harbor latent HIV-1 is 
the tissue resident memory T cell (TRM) populations (198, 199).  Pioneering studies in the 
murine system demonstrated wide distribution of memory CD4+ T cells, including in non-
lymphoid tissues such as liver and lung (190).  Subpopulations of memory cells may be 
generated in or recruited to particular non-lymphoid tissues where they reside for long 
periods of time (192, 199).  These TRM lack expression of CCR7 and share phenotypic and 
functional properties with TEM.  However, unlike other memory subsets, they express CD69, 
a cell surface lectin that is upregulated at early times following T cell activation.  In humans, 
the majority of TEM cells in lymphoid and mucosal tissues, including lungs and intestines, 
express CD69 and therefore may be retained in these sites as TRM (191, 200).  Human skin 
also contains significant TRM populations (198).  Thus far, TRM have not been directly 
examined for the presence of latent HIV-1.  However, persistent HIV-1 has been detected 
in gut-associated lymphoid tissue of individuals on ART (201, 202).  TRM are prominent in 
the lamina propria and among intraepithelial lymphocytes, and it is possible that TRM 
harbor HIV-1.  Many CD4+ TRM exhibit activated phenotypes, with reduced surface 
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expression of CD28 (191), and therefore it is unclear whether latent infection can be 
established in these cells.  Further characterization of tissue-specific reservoirs for HIV-1 
is an important research priority.   
 
Evidence for clonal expansion of infected cells  
Consideration of the mechanism of memory cell homeostasis suggests that the stability of 
the latent reservoir is at least partially dependent upon the ability of infected cells to 
proliferate.  Several studies have provided direct evidence for clonal expansion of infected 
cells, beginning with studies RV (100, 102).  Although patients starting ART during 
chronic infection harbor diverse viral quasispecies (138), the RV is often dominated by 
identical sequences detected on independent sampling over months to years.  The origin of 
these sequences is unknown but may reflect infection of cells that then proliferate giving 
rise to multiple progeny cells carrying identical proviruses (100, 102, 203).  The fraction 
of identical HIV-1 sequences within samples from patients on ART increases with time, 
consistent with proliferation of infected cells (145).  More recent studies have used 
integration site analysis to provide definitive evidence for the proliferation of infected cells.  
The sites of integration in different cells are generally different and are distributed widely 
throughout the human genome.  Early studies in cell lines infected in vitro with HIV-1 (204) 
and in resting CD4+ T cells from patients on ART (205) revealed a strong preference for 
integration within active transcriptional units.  However, integration occurs in either 
orientation with respect to the host gene, and there is no consensus sequence at the 
integration site.  Therefore, the precise human sequence at the junction between host and 
HIV-1 DNA uniquely identifies individual infection events and thus all the clonal progeny 
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of a single infected cell.  In addition, novel deep sequencing analysis allows enumeration 
of the clonal progeny of a single infected cell within a sample by detection of differences 
in the random break points in fragments of sheared DNA containing the same integration 
site (170, 206).   Application of this and related approaches to CD4+ T cells from patients 
on ART has provided dramatic evidence for clonal expansion (170, 171, 207).  Maldarelli 
et al. showed 43% of 2410 integration sites in CD4+ T cells from 5 patients were in clonally 
expanded cells (170).  The finding that multiple cells with the same integration site can be 
captured in a single blood sample reflects dramatic clonal expansion in vivo. 
Interestingly, some expanded clones had proviruses integrated in human genes 
associated with cell growth, and some of these genes have been observed to contain 
integrated proviruses in multiple independent studies (170, 171, 205, 207, 208).  These 
include myocardin-like protein 2 (MKL2), a transcription factor, and basic leucine zipper 
transcription factor 2 (BACH2), a transcription regulator affecting lymphocyte growth, 
activation, senescence, and cytokine homeostasis.  For these genes, integration events were 
found in a specific region of the gene and in the same transcriptional orientation as the host 
gene.  This skewed pattern reflects a post-integration selection process that favors the in 
vivo growth and survival of cells with those integration events since these patterns were 
not seen in in vitro infections (170, 171, 204).  These results raise the interesting possibility 
that integration into certain host genes contributes to HIV-1 persistence by stimulating 
infected cells to proliferate in a manner distinct from homeostatic proliferation.  The 
molecular mechanisms are currently unclear.  
A caveat to these studies is that the methods used do not capture the full sequence 
of the integrated provirus.  Some methods capture only the junction between host and HIV-
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1 DNA.  Given that the vast majority of proviruses are defective, as a result of large internal 
deletions or APOBEC3G-mediated hypermutation (189, 207), it must be assumed that 
most expanded clones carry defective proviruses. There is no selective pressure against 
cells carrying defective proviruses that do not produce viral proteins.  Previous studies have 
described expanded clones carrying defective proviruses, some of which persist for many 
years (22, 209).   However, a recent report has described dramatic in vivo expansion of an 
infected CD4+ T cell clone in a treated patient who also had squamous cell carcinoma (210). 
Importantly, this clone was capable of producing replication-competent virus.  The 
integration site could not be precisely localized because it was in a region of repetitive 
sequence.  The clone was found widely distributed in sites of metastatic tumor throughout 
the body, raising the possibility that the clonal expansion occurred in response to tumor 
antigen.  A current issue of great importance is the extent to which expanded cellular clones 
harbor replication-competent HIV-1. 
 
Implications 
The stability of the latent reservoir is the principal reason that HIV-1 infection cannot be 
cured.  The normal mechanisms that maintain immunologic memory provide a simple 
explanation for this stability.   However, the pool of latently infected cells is not static.  
While the total pool size decreases only very slowly, cells in the reservoir are continually 
being activated to produce virus that is evident as residual viremia.   These cells may die, 
but homeostatic proliferation of memory cells helps to balance the loss.  In addition, a more 
cell autonomous process of proliferation driven by integration-site dependent alterations in 
host gene expression may allow some infected cells to undergo dramatic clonal expansion. 
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Efforts to target the latent reservoir have generally assumed that intervention-dependent 
reductions in the frequency of latently infected cells will be stable so that repeated 
interventions will ultimately allow cure.  The possibility that subpopulations of infected 







Figure 1.1.  Model for the establishment of latent HIV-1 infection in resting memory 
CD4+ T cells.  The normal process of memory cell generation (boxed) involves the exposure of 
a resting CD4+ T cells to antigen which leads to blast transformation, proliferation, and 
differentiation into effector cells.  Many effector cells die during the contraction phase of the 
immune response, but a fraction survive and gradually return to a quiescent state as long-lived 
resting memory cells.   Most resting CD4+ T cells lack expression of CCR5, a critical coreceptor 
for HIV-1 entry.  Activation of resting cells by antigen (Ag) upregulates CCR5 expression and 
reverses other blocks to HIV-1 replication in resting CD4+ T cells, allowing productive infection 
of these cells.  Most productively infected CD4+ T lymphoblasts die rapidly from activation-
induced cells death (AICD), viral cytopathic effects (CPE), or lysis by CTL.  As activated cells 
transition back to a resting state, active forms of key host transcription factors needed for HIV-1 
gene expression are sequestered.  Infection at this stage may lead to latent infection rather than cell 





Fig. 1.2.  Dynamics of the latent reservoir.  ART largely blocks new infection of susceptible 
cells.  In patients on long term ART, the pool of latently infected cells is extremely stable (t½ = 3.7 
years) so that memory cell turnover must be largely balanced by proliferation of previously infected 
cells. Latently infected resting memory CD4+ T cells occasionally encounter the relevant cognate 
antigen (or a cross-reacting antigen) and become activated.  Activation reverses latency, allowing 
viral gene expression and virus production.  In patients on ART, the released viruses do not 
successfully infect new cells, but may be detected at very low levels in the plasma where they 
constitute the residual viremia (RV).  Most productively infected cells die quickly from AICD, 
CPE, or lysis by CTL.  It is possible that some degree of antigen-driven proliferation may occur 
without activation of viral gene expression.  Homeostatic proliferation of memory cells may also 
occur without reactivating viral gene expression.  For some infected cells, integration of the 
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Targeting the latent HIV-1 reservoir:  challenge for a cure 
Despite the efficacy of antiretroviral therapy (ART) in suppressing HIV-1 replication, there 
is still no cure for HIV-1 infection due to the presence of a latent reservoir for the virus (1). 
This latent reservoir consists mainly of resting memory CD4+ T cells harboring integrated 
HIV-1 proviruses. The reservoir has an extremely slow decay rate such that viral 
eradication by ART alone is not possible (1). Recent studies have shown that one of the 
major mechanisms of reservoir persistence is the clonal expansion of these latently infected 
cells. Initial evidence for this route of persistence came from the independent detection of 
multiple proviruses with exactly the same viral sequence or integration site within host 
cells (2–6). Full genome sequencing studies have established that most proviruses present 
in resting CD4+ T cells are defective (6–8), and thus many of these proviruses are unlikely 
part of the latent reservoir. Nevertheless, recent work from several groups has 
demonstrated that cells carrying replication-competent proviruses can also clonally expand 
in vivo (9–12). The proliferation of cells carrying intact, replication-competent proviruses 
is a troubling finding that helps explain the stability of the HIV-1 reservoir and raises 
concerns about the feasibility of eradication.  
 
Growing evidence for clonal expansion  
Clonal expansion is a basic aspect of normal T cell biology. Antigen-driven proliferation 
and cytokine-driven homeostatic proliferation are well established as mechanisms by 
which T cell populations expand(13). However, it has been less clear as to whether or not 
infected CD4+ T cells can proliferate, especially as  productively infected cells have a very 
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short in vivo half-life (14,15). Early evidence for clonal expansion of HIV-1-infected cells 
came from studies of residual viremia, the trace level of free virus detectable in the plasma 
of treated patients with special methods. Despite the extensive viral sequence 
diversification that occurs over time in untreated patients, the residual viremia observed 
once patients start a suppressive ART regimen is often surprisingly oligoclonal, suggesting 
that it is produced by expanded cellular clones carrying exactly the same proviruses(16,17). 
However, an alternative explanation for viral sequence identity is that multiple cells are 
infected by a single dominant viral variant. Definitive proof that clonal expansion of 
infected cells has occurred can be obtained by demonstrating that these cells carry the same 
proviral sequence integrated at the same exact position in the human genome. After the 
development of next-generation sequencing technologies that allowed for efficient 
integration site sequencing, several groups reported the detection of expanded clones based 
on the presence of identical integration sites (3-5); however, integration site analysis 
captures only the very end of the viral genome. Given that the majority of proviruses are 
defective, these studies establish the clonal expansion of infected cells but do not 
necessarily identify those carrying intact viral genomes. One interesting concept to come 
out of these studies was the idea that proviral integration into particular host genes might 
alter expression of those genes in a way that promotes cell proliferation and/or survival 
(2,3).  
 Recently, several groups have provided evidence for the clonal expansion of cells 
carrying replication-competent proviruses (9–12). Simonetti and colleagues identified an 
integration site associated with a single, dominant CD4+ T cell clone carrying a replication-
competent provirus in an HIV-1-infected patient with squamous cell carcinoma (9). 
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Interestingly, the clonally expanded T cells were found at sites of the disseminated 
malignancy in this patient, raising the possibility of antigen-driven expansion. In addition, 
three groups recently showed that multiple CD4+ T cells carrying identical, replication-
competent proviruses are often present in a single blood sample from treated patients (10–
12). In all three studies, the fraction of viral isolates that had sequence exactly matching 
another independent isolate from the same sample was over 50%.  With additional 
sampling, it is likely that matching sequences could be found for most if not all of these 
isolates.  Together, these findings suggest that the majority of cells comprising the latent 
reservoir are generated by the proliferation of a smaller number of previously infected cells 
rather than by direct infection.  These results do not support the idea that de novo infection 
events are a major factor in reservoir stability as has been recently suggested (18). Rather 
it appears that the remarkable stability of the latent reservoir is largely due to cellular 
proliferation. 
 How can we reconcile the strong evidence for proliferation with the short in vivo 
half-life of productively infected cells? In the studies described above, the clonal T cell 
populations carrying replication-competent proviruses were demonstrated using variations 
of the viral outgrowth assay in which limiting dilutions of resting CD4+ T cells are activated 
with a mitogen and replication-competent viruses are allowed to grow out.  In one study, 
restimulation of cultures that were negative for viral outgrowth, despite uniform T cell 
activation with mitogen, resulted in additional outgrowth of replication-competent 
viruses12. These findings show that CD4+ T cells carrying replication-competent proviruses 
can proliferate without producing virus while retaining the ability to do so upon subsequent 
stimulation12. Thus, proliferation need not be limited by the short half-life of productively 
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infected cells.  It is unclear what prevents some latent proviruses from being induced upon 
cellular activation. The fact that cells carrying replication-competent proviruses can 
multiply while evading immune recognition presents a major challenge to current cure 
strategies and attempts to eradicate the latent reservoir.  
 
The role of proliferation in persistence of the reservoir  
The normal decay of cells in the latent reservoir may be balanced by proliferation of cells 
with latent provirus, thus resulting in the long observed half-life of the reservoir (19,20). 
However, the dynamics of various subpopulations of CD4+ T cells in the context of HIV-
1 infection are not well understood, and most studies are limited to peripheral blood 
samples. More studies on the proliferation of various populations of infected cells in tissue 
compartments would be beneficial in determining the natural dynamics of the latent 
reservoir.  Latent proviruses are present in various CD4+ T cells subsets (13,21,22). For 
example, previous studies from Lichterfeld and colleagues have described the presence of 
proviral DNA in a small, long-lived population of CD4+ memory T cells with stem cell 
properties (21). In this issue, Lee et al. apply a full genome sequencing approach to evaluate 
functional subsets of CD4+ T cells (23). Cells were sorted based on the production of 
signature, subset-defining cytokines, and cellular DNA was subjected to full genome 
sequencing of the proviruses present.   Consistent with previous studies, Lee et al found 
that the vast majority of proviruses are defective. They also determined that independent 
sequences that were identical to other sequences from the same patient comprise over half 
of all intact sequences detected, consistent with previous studies of replication-competent 
isolates23.  Importantly, Lee et al. report that there is an enrichment of clonally expanded 
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intact proviruses in functionally-polarized Th1 cells (23) as depicted in Figure 1, adding to 
Lichterfeld and colleagues’ previous findings of enriched integration in Th1 cells (22). 
While clonal expansion of cells harboring defective proviruses was also observed, intact 
proviruses were enriched in circulating Th1-polarized cells. Lee and colleagues propose 
that the virus may exploit the relatively high proliferation rate of Th1 cells to propagate via 
the division of infected host cells (23).  It would be of interest to compare the proliferation 
and dynamics of infected and uninfected Th1 cells to further assess the role of proliferation 
of specific functional subsets on viral persistence. If the reservoir is largely maintained by 
natural host physiological mechanisms, it may be difficult to develop cure strategies that 
block proliferation without affecting normal T cell homeostasis.  
 
Concluding remarks 
Overall, the study by Lee et al. adds to the growing consensus that persistence of the latent 
reservoir of HIV-1 may be due in large part to the clonal expansion of cells harboring intact, 
replication-competent virus. Both homeostatic, cytokine-driven proliferation and antigen-
stimulated proliferation may contribute to viral persistence, and both forms of proliferation 
have been shown to occur without reactivation of latent proviruses (12,24). In either case, 
it may be difficult to block proliferation and reduce the size of the latent reservoir without 
creating negative consequences for patients. Here, methods to selectively block 
proliferation may be key. A growing number of studies and several clinical trials are 
evaluating immunosupressive agents that may block proliferation and decrease the number 
of cells carrying potentially infectious proviruses. Recent clinical studies involve 
immunosuppressants such as tacrolimus or sirolimus that are usually administered in the 
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setting of organ transplantation. There is evidence for decreased levels of HIV-1 DNA in 
patients treated with some immunosuppressants (25). Further investigation of the direct 
effects of immunosuppressants on the reservoir are needed to determine whether blocking 






Fig. 2.1. Intact, clonally expanded HIV-1 proviruses in Th1 subpopulation. (A) CD4+ T cells 
differentiate into functional subsets, each of which is characterized by a defining transcription 
factor (TF) and a set of cytokines produced following activation. In this issue, Lee et al. sorted 
peripheral blood mononuclear cells from 3 cART-treated patients into CD4+ T cell 
subpopulations based on production of 4 signature cytokines (blue). Subsets not examined are 
labeled as such. Cellular activation induces virus production from latently infected CD4+ T cells 
(B). Differentiated T cell subsets carrying replication-competent (C) or defective (D) proviruses 
can also be stimulated to proliferate. In the patients studied by Lee et al., clonally expanded, 
intact proviral sequences were predominantly in the largest subset, Th1 cells. See Supplemental 
Table 3 in ref. 23. Tfh, T follicular helper.  
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A latent reservoir for HIV-1 in resting CD4+ T-lymphocytes precludes cure.  Mechanisms 
underlying reservoir stability are unclear. Recent studies suggest an unexpected degree of 
infected cell proliferation in vivo.  T-cell activation drives proliferation but also reverses 
latency resulting in productive infection that generally leads to cell death.  We show that 
latently infected cells can proliferate in response to mitogens without producing virus, 
generating progeny cells that can release infectious virus. Thus, assays relying on one 
round of activation underestimate reservoir size.  Sequencing of independent clonal isolates 
of replication-competent virus revealed that 57% had env sequences identical to other 
isolates from the same patient.  Identity was confirmed by full genome sequencing and was 
not attributable to limited viral diversity.  Phylogenetic and statistical analysis suggested 
that identical sequences arose from in vivo proliferation of infected cells rather than 
infection of multiple cells by a dominant viral species.  The possibility that much of the 




A stable latent reservoir for HIV-1 in resting memory CD4+ T cells persists despite 
antiretroviral therapy (ART)1-9.  The extremely long half-life of this reservoir is a major 
barrier to  cure6-9. This reservoir of latent but replication-competent HIV-1 was originally 
identified in resting CD4+ T cells in the blood and lymph nodes1,2, but known patterns of 
circulation, activation, and differentiation of memory T cells predict that persistent HIV-1 
resides in multiple memory cell subsets in multiple tissues10-14.  The latent reservoir is a 
major target of cure efforts, some of which focus on reversing latency so that infected cells 
can be eliminated by immune mechanisms15-18. 
One potential explanation for the remarkable stability of the latent reservoir 
involves the proliferation of infected cells10,19-25.  Proliferation of infected cells is to some 
extent unexpected.  Some stimuli that drive T cell proliferation also drive latently infected 
cells into a productively infected state, and productively infected cells have a very short 
half-life (1 day)26,27.  In addition, the HIV-1 Vpr protein causes cell cycle arrest28-35.  In 
some model systems, cytokines including IL-7 and IL-15 can drive homeostatic 
proliferation of CD4+ T cells without inducing virus gene expression21,36.  However, IL-7 
can also reverse latency in some systems37,38. 
Despite the issues raised above, there is considerable evidence that infected cells 
can proliferate in vivo.  The evidence comes in two forms.  In patients who start 
antiretroviral therapy during chronic infection, extensive viral sequence diversification 
takes place prior to treatment39,40, making it unlikely that multiple independently sampled 
viral sequences from a single patient will be identical.  Therefore, repeated isolation of 
identical viral sequences from individual patients can be most readily explained by 
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assuming that an initially infected cell carrying the sequence subsequently proliferated, 
copying the integrated viral genome without error into progeny cells.  Sequencing of trace 
levels of plasma virus present in treated patients initially provided the surprising result that 
this residual viremia was often dominated by a single frequently isolated sequence19,20.  
Subsequent studies of proviral DNA also revealed independent identical sequences20,25,41,42. 
Although these studies strongly suggest in vivo proliferation of infected cells, there are 
caveats.  Isolates that are identical in the sequenced part of the genome may differ 
elsewhere and not be clonal43 or may represent separate infection events with an identical 
virus.  Furthermore, the vast majority of proviruses are defective42,44,45, and without full 
genome sequencing44 or viral outgrowth assays25, it remains unclear whether the identical 
sequences represent replication-competent virus. An important recent study by Lorenzi et 
al. has examined a large number of independent isolates of replication-competent virus 
from treated patients and found that over 50% share sequence identity in the env gene with 
other isolates from the same patients25. 
Definitive evidence for the proliferation of infected cells’ virus has come from an 
experimental approach involving the analysis of HIV-1 integration sites.  Recent studies 
have demonstrated that within a given patient, a surprisingly large fraction of infected 
CD4+ T cells shows proviral integration into precisely the same position in the human 
genome22,23,46.  Given the relatively non-specific integration of HIV-1 into expressed genes 
throughout the genome47,48, this result can only be explained by the proliferation of infected 
cells after integration.  Interestingly, some of the expanded clones showed integration into 
cellular genes associated with cell survival and/or proliferation, raising the possibility that 
altered host gene expression could drive proliferation22,23.   However, integration site 
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analysis captures only the ends of the viral genome, and it is likely that most of the 
expanded cellular clones detected by integration site analysis are replication defective, as 
has been shown by Cohn et al. 46.  Unfortunately, with current methods, it is difficult to 
simultaneously and efficiently obtain both the integration site and the full proviral sequence.  
Interestingly, a recent report by Simonetti et al. has described a massively expanded CD4+ 
T cell clone carrying replication-competent virus in a patient with a complex disease 
course24. 
Taken together, the above results raise the interesting possibility that the 
proliferation of infected cells may contribute to the stability of the latent reservoir.  To 
explore this issue, we have carried out ex vivo stimulations and single genome analysis to 
look for evidence of clonal expansion in infected individuals on ART. 
Materials and Methods 
Study Subjects.  Subjects were HIV-1 infected adults who met the inclusion criteria of 
suppression of viremia to <20 copies HIV-1 RNA/ml of plasma on ART for >6 months. 
This study was approved by the Johns Hopkins Institutional Review Board.  Written 
informed consent was obtained from all subjects. 
Multiple Stimulation Viral Outgrowth Assay (MS-VOA).  The MS-VOA was performed on 
purified resting CD4+ T cells as described previously44,50,51 with modifications to allow 4 
consecutive stimulations with PHA (Fig. 1a,b).  Resting CD4+ T cells were isolated from 
PBMC using a two-step negative selection protocol51 with monoclonal antibodies and 
magnetic beads (Miltenyi Biotec) as previously described and plated in the upper chambers 
of 12-well transwell plates (Corning) at a predetermined limiting dilution for viral 
outgrowth (200,000 cells per well).   Cells were activated with PHA (0.5 ug/mL) and 
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irradiated allogeneic PBMC from uninfected donors as previously described1-3.  The 
following day, half the media from each transwell was removed and replaced with fresh 
media lacking PHA, and then 106 MOLT-4/CCR5 cells3 were added to the bottom chamber 
of the transwell to allow robust replication of virus released from infected cells.  Previous 
studies have shown that viral outgrowth in this transwell system is equivalent to that seen 
with direct co-culture44.  MOLT-4/CCR5 cells were obtained from the NIH AIDS Reagent 
Program and were maintained in G418 until use in the assay.  The cells tested for CCR5 
expression by flow cytometry and were negative for mycoplasma.  Eight days after the 
initial PHA stimulation, half of the volume from both the top and bottom chambers of each 
transwell was transferred to a new set of transwell plates for a second round of PHA 
stimulation. The initial plates were cultured without further stimulation for a total of 21 
days. The restimulated plates were cultured for 8 days following the second round of PHA 
stimulation and then split as above to generate a third set of plates, which received a third 
round of stimulation. Similarly, these plates were split 8 days later to generate the fourth 
set of plates, which received a fourth round of stimulation. A p24 ELISA (PerkinElmer) 
was performed on the supernatant 21 days after each respective round of PHA stimulation 
(Fig. 1b).  
CFSE dilution and activation/exhaustion marker staining.  An aliquot of resting CD4+ T 
cells was stained with 5 uM CFSE prior to the initial PHA stimulation. The dilution of 
CFSE was analyzed 1 week later by flow cytometry using a 488 nm laser on a BD 
FACSCANTO II cytometer (BD Biosciences) with an emission of 492⁄517 nm.  
Unstimulated cells served as a control.   Expression of activation markers was analyzed 1 
week after each round of PHA stimulation.  An aliquot of cells was stained with anti-CD4 
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(FITC), anti-CD25 (APC), anti-CD69 (APC), and anti-HLA-DR (APC) antibodies 
(BioLegend, San Diego, CA) at 4o C for 15-30 minutes and analyzed by flow cytometry 
on BD FACSCANTO II cytometer (BD Biosciences). Cells that did not receive the most 
recent round of PHA stimulation served as controls.  To assess changes in expression of 
inhibitory receptors, cells were stained a week after each round of PHA activation with 
anti-PD1 (FITC), anti-CTLA-4 (PE), and anti-Tim-3 (P3/Cy7) antibodies (BioLegend, San 
Diego, CA) and analyzed by flow cytometry.   
RNA isolation, cDNA synthesis and amplification of the env gene.  Viral RNA was isolated 
from 200 µL of the supernatant from each p24+ well using a ZR-96 Viral RNA Kit™ 
(Zymo Research Corporation, Irvine, CA). RNA was then treated with DNase (Life 
Technologies, Carlsbad, CA) and reverse transcribed using the qScript cDNA Supermix 
kit (Quanta Biosciences, Gaithersburg, MD).  Since the cultures were seeded at limiting 
dilution for viral outgrowth, we ran a nested PCR on undiluted cDNA from each well.  A 
nested PCR for the V3/V4 region of env was performed using 600 ng of cDNA and primers 
ES7 (CTGTTAAATGGCAGTCTAGC) and ES8 (CACTTCTCCAATTGTCCCTCA) for 
the outer reaction. The outer PCR products were diluted 1:50 and 5 µL of this dilution were 
used for the inner PCR reaction with primers Nesty8 (CATACATTGCTTTTCCTACT) 
and DLoop (GTCTAGCAGAAGAAGAGG).  Primers were obtained from Integrated 
DNA Technologies (Coralville, IA). Amplification conditions were as follows: 
denaturation at 94oC for 3 min, followed by 40 cycles of denaturation at 94oC for 30 sec 
annealing at 55oC for 30 sec, and extension at 68oC for 5 min.  PCR products were run on 
a 1% agarose gel, and bands were extracted using the QIAquick Gel Extraction Kit (Qiagen, 
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Hilden, Germany). Extracted DNA was analyzed directly by Sanger sequencing at 
Genewiz, Inc. (Frederick, MD).  
Amplification of the env gene from proviral DNA.  Nested PCR carried out at limiting 
dilution was used to analyze the env gene of proviruses in resting CD4+ T cells from study 
subjects.  Amplification was carried out as previously described20, except the outer PCR 
primers were the ES7/ES8 described above.  1 µL of the outer PCR product was used for 
the inner PCR reaction, with the Nesty8/DLoop primers described above.  PCR products 
were directly sequenced as described above. 
Full genome sequencing.  For representative isolates, viral RNA was sequenced by single 
genome amplification as previously described54.  Viral RNA in the supernatants of p24+ 
wells was extracted and reverse transcribed.  cDNA was serially diluted and amplified with 
nested PCRs in two overlapping half genome reactions as described705.  For each isolate, 
6-12 amplicons obtained at the limiting dilution were directly sequenced and a full genome 
consensus sequence was generated as described in the text. 
Phylogenetic analysis.  Forward and reverse sequences for each sample were aligned into 
a single consensus contig per sample using default assembly parameters on CodonCode 
Aligner software (CodonCode Corporation).  Rare sequences that did not appear clonal 
were discarded.  Each sample consensus sequence was aligned with reference sequences 
of catalogued viruses from the Los Alamos National Laboratory HIV sequence database 
(http://hiv.lanl.gov) using default assembly parameters that were adjusted to accommodate 
all sample and reference sequences. For phylogenetic tree generation, sequences were 
trimmed to the same length.  Genetic distances were calculated and neighbor joining trees71 
were generated using a maximum composite likelihood algorithm and default parameters 
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using MEGA7 software (Molecular Evolutionary Genetics Analysis Program)72  
Maximum likelihood trees were also generated.  The conclusions were not sensitive to the 
method of tree generation, and neighbor joining trees are shown in the figures.    
Data availability.  Sequences are available through Genbank (Accession numbers pending). 
Statistical test for clonal proliferation.  We designed a statistical analysis based on 
coalescent theory to explore the possibility that the high degree of sequence identity 
observed could be explained merely by rounds of viral replication in which no mutation 
occurred.  The test was applied to a subset of study participant (01, 03, 10, 11, and 12) for 
whom a single large set of identical isolates that were phylogenetically distinct from 
smaller sets and unique individual sequences (singletons) from the same participant (Figure 
3).  For the other participants, the test could not be readily applied because there were either 
no singletons (02), no gap between small and large sets (05, 06), or no unique large clone 
after the gap (09). For each patient, the mutation parameter estimate 𝜃  was chosen to 
maximize the likelihood of observing the configuration according to Ewens’ sampling 
formula for the coalescent58. This calculation provides the nested model likelihood for the 
statistical test, (i.e., likelihood without clonal proliferation).  Clonal proliferation is 
assumed to alter the isolate set configuration by taking one sequence and increasing its 
multiplicity, by a mechanism other not present in the standard coalescent model. To model 
this behavior, we suppose that the proliferating sequence is (one of) the most frequent 
sequences observed, and that it effectively replaced a number of singleton sequences that 
would have otherwise been observed in the sample. To maximize the likelihood, there are 
now two parameters: the mutation parameter (as in the nested model), and the number of 
sequences that this largest clone effectively replaced. We again use Ewens’ sampling 
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formula, but on an isolate set configuration that is modified to reverse the effect of this 
supposed replacement. In other words, the largest clone is shrunk, and singleton sequences 
are added to keep the total sample size the same. The mutation parameter estimate 𝜃 and 
log-likelihood are computed for this modified configuration. A p-value is obtained using 
the likelihood ratio test with one degree of freedom.  
Results 
Analysis of infected cell proliferation using a multiple stimulation viral outgrowth 
assay 
Given that productively infected cells have a short in vivo half-life (1 day)26,27, we 
hypothesized that proliferation of latently infected cells carrying replication-competent 
HIV-1 could take place without release of infectious virus.  To test this hypothesis, we 
subjected resting CD4+ T cells from patients on long term ART to multiple rounds of 
mitogen stimulation   in order to detect virus release from cells that had proliferated in 
response to a previous stimulation without producing infectious virus.  This assay, 
modified from the standard quantitative viral outgrowth assay (QVOA)2,3,6,8,49-51 used to 
measure the frequency of latently infected cells, is described in Figure 1.   Limiting 
dilutions of purified resting CD4+ T-cells were maximally stimulated with the potent T cell 
mitogen phytohemagglutinin (PHA) and irradiated allogeneic peripheral blood 
mononuclear cells (PBMC) from uninfected donors.  CCR5-transfected MOLT4 cells 
(MOLT4/CCR5)50 were added to expand virus released from cells in which latency was 
reversed. Patient cells and MOLT4/CCR5 cells were plated in separate chambers of 
transwell plates.  This allows separate manipulation of patient cells while giving T-cell 
activation and viral outgrowth equivalent to standard co-cultures44.  After 8 days, half the 
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contents of each well were transferred to the corresponding chambers of new plates which 
received an additional stimulation.  The original plates were cultured without the additional 
stimulation for a total of 21 days (Fig. 1b).  A total of four sequential stimulations were 
performed in this manner.   Each well was cultured for 21 days after the most recent 
stimulation, sufficient time to allow virus released from a single cell to grow exponentially 
in MOLT4/CCR5 cells to levels readily detectable by p24 ELISA50.  Viral RNA in the 
supernatants of p24+ wells was then subjected to sequence analysis. This protocol allows 
assessment of whether cells that have previously proliferated in response to T cell 
activation without producing infectious virus can release virus with additional stimulation 
(Fig. 1b). 
The initial stimulation caused >99% of patient resting CD4+ T cells to proliferate 
(Fig. 1c). Cell number increased 8-fold during the first week with smaller increases after 
the 2nd, 3rd, and 4th stimulations (3.5-, 2.5-, and 2-fold respectively; Fig. 1d). The initial 
stimulation also caused >99% of the cells to express T cell activation markers (Fig. 1e).  
Although cells did not return to a fully quiescent state before the 2nd, 3rd, and 4th 
stimulations, each stimulation increased activation marker expression relative to cells that 
did not receive the most recent stimulation (Fig. 1e). 
This multiple stimulation viral outgrowth assay (MS-VOA) was performed on 
purified resting CD4+ T cells from 12 participants (01-12) on long-term suppressive ART 
(see Supplementary Table 1 for patient characteristics).  The mean frequency of latently 
infected cells detected after with the first stimulation was 0.83 infectious units per million 
(IUPM) resting CD4+ T cells, not significantly different from that observed in studies using 
the standard QVOA6,8,52.  However, for every subject, the additional rounds of stimulation 
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caused viral outgrowth in cultures split from wells that remained negative for viral 
outgrowth without the additional stimulation (Fig. 2a).  Because all cells proliferate in 
response to PHA (Fig. 1c), this result indicates that some latently infected cells proliferated 
without releasing infectious virus but retained the capacity to do so following subsequent 
stimulation.  These results are consistent with previous work showing that a single round 
of stimulation in the standard QVOA does not detect all the latent virus present44 and with 
studies in a primary cell model showing that cytokine-driven homeostatic proliferation of 
latently infected cells can occur without upregulation of HIV-1 gene expression21. 
These studies provided insight into the relationship between T cell activation, 
proliferation, and latency reversal.  By splitting cultures of proliferating CD4+ T cells, it is 
possible to determine whether additional stimulation can induce virus production when 
other cells from the same clonal population fail to produce virus after the initial stimulation.  
Of all cultures that eventually become positive for outgrowth, only an average of 60% were 
detected after the first stimulation (Fig. 2b).  In 11 of 12 patients, two rounds of stimulation 
were insufficient to induce all of the proviruses that were ultimately induced with the third 
or fourth rounds (Fig. 2a, b).  These results illustrate the difficulty in purging the latent 
reservoir even with maximum T cell activation.  Multiple rounds of maximal stimulation 
are likely to be required.  However, in 4 of 12 participants, 70-80% of isolates were 
obtained in the first round of stimulation.  Interestingly, because cell number increased 
with each stimulation (Fig. 1d), the per-cell probability of outgrowth fell after the first 
stimulation (Fig. 2c).  This may reflect differences in proviral inducibility, with a readily 
induced population and a generally smaller population that is more difficult to induce.  
Alternatively, changes in the transcriptional environment with repetitive stimulation during 
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long term in vitro culture might prevent induction of some intact proviruses that could be 
induced in vivo.  To address this possibility, we examined CD4+ T cell expression of 
surface proteins associated with functional inhibition or immune exhaustion53, including 
PD-1, CTLA-4, and Tim-3. We observed increased Tim-3 expression after multiple 
stimulations (Fig. 2d). Exhaustion of the cells in culture may contribute to the consecutive 
decreases in the probability of outgrowth.  Thus, the MS-VOA provides only a minimal 
estimate of latent reservoir size because immune exhaustion developing with repetitive 
stimulation and/or long term in vitro culture may not allow outgrowth from all potentially 
inducible replication-competent proviruses. The frequency of latently infected cells 
detected with the MS-VOA was ~2 fold greater than the standard QVOA value measured 
after one round of stimulation (Fig. 2e).  The actual frequency of latently infected cells is 
likely to lie between the MS-VOA measurement and the total number of intact (non-
defective) proviruses (Fig. 2f).  Together, these results demonstrate that latently infected 
cells carrying replication-competent HIV-1 can proliferate in response to ex vivo 
stimulation without producing infectious virus while retaining the ability to do so 
subsequently. 
 
Independent isolation of identical sequences of replication-competent virus from the 
latent reservoir 
The ability of latently infected cells to proliferate ex vivo without releasing virus suggests 
that in vivo clonal expansion of infected cells could maintain the latent reservoir.  If 
expanded cellular clones comprise a significant fraction of the latent reservoir, then it 
should be possible to obtain from individual patients independent isolates of replication-
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competent virus with identical sequence throughout the viral genome.  We were able to 
directly test this prediction in a unique way because of the large number of independent 
isolates of replication-competent HIV-1 obtained at limiting dilution following different 
rounds of stimulation in the MS-VOA.  We first amplified by RT-PCR the highly variable 
V3-V4 region of the env gene from viral RNA in supernatants of all p24+ wells from the 
MS-VOA from all 12 study subjects.   Because the cells were initially plated at limiting 
dilution for viral outgrowth, most positive wells contained only a single sequence, and 
wells with multiple sequences were discarded.  Sequences from each subject clustered 
together and separately from other subjects in phylogenetic analysis (Supplementary Fig. 
1).  Although all participants started ART during chronic infection (Supplementary Table 
1), 9 of 12 subjects had one or more sets of independent isolates with identical sequence in 
the highly variable V3-V4 region of the env gene (Fig. 3).  Sets of isolates with identical 
env sequences were seen in 9 of 9 patients from whom >10 isolates were obtained, strongly 
suggesting this phenomenon is general.  It is important to note that isolates with identical 
env sequences are not the result of in vitro proliferation - all of these isolates originated 
from different wells of the original tissue culture plates (Fig. 1b), indicating they are 
derived from different infected cells present in vivo.  Of 197 independent isolates from 12 
subjects, 113 (57%) belonged to sets of isolates with identical env sequences while the 
remaining 43% had unique env sequences (Fig. 3). 
 
Isolates with identical env sequences are identical throughout the HIV-1 genome 
These results are consistent with the idea that the majority of latently infected cells arise 
from proliferation of a smaller number of previously infected cells.  However, alternative 
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explanations must be excluded.  First, it is possible that isolates with identical env 
sequences differ elsewhere in the genome43.  To address this possibility, we first 
determined the Clonal Prediction Score (CPS), a measure of the ability of subgenomic 
amplicons to predict clonality43.  For this env amplicon, the CPS was 96, meaning that 96% 
of the time sequences identical in this region are identical throughout the entire viral 
genome based on available full genome sequences from viral outgrowth assays.  To provide 
direct experimental evidence that isolates with identical env sequences were identical 
throughout the entire HIV-1 genome, we used single genome analysis of genomic viral 
RNA in the supernatants of p24+ wells to obtain the full genome sequences of 
representative isolates belonging to sets of isolates with identical env sequences.  The 
sequencing was carried out on two overlapping half-genome fragments.  We were able to 
produce full genome sequences from the half-genome sequences because the overlap 
regions were identical, and more importantly, because only a single provirus gave rise to 
outgrowth in these limiting dilution cultures.  Although defective proviruses may have been 
present in these cultures, the profound nature of the commonly observed defects42,44,45 
would preclude virion release into the supernatant.  For each isolate tested, 6-12 single 
genome sequences were obtained at limiting dilution from RNA in the supernatant.  To 
avoid PCR errors, PCR products were sequenced directly without cloning54.  Sequences 
for each isolate were identical or very similar (Fig. 4a), with 1-4 nucleotide differences 
likely representing the expected variation55 arising during the three week culture period 
used to obtain each isolate (Fig. 1b).  Importantly, single genome sequences from different 
isolates belonging to a given set with identical env sequences were intermingled in 
phylogenetic analysis (Fig. 4a).  The genetic distances between sequences from the same 
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isolate and from other isolates belonging to the same set were not significantly different 
and were much smaller than the genetic distance between sequences from a given set and 
other isolates from the same subject (Fig. 4b).  The consensus half-genome sequences for 
each isolate were used to construct full genome sequences.  Phylogenetic analysis of full 
genome sequences again showed that isolates with identical env sequence clustered 
together in a monophyletic pattern (Fig. 4c). Together, these results demonstrate that 
isolates with identical env sequence are identical throughout the genome. 
 
Dominant viral sequence vs. clonal expansion 
There are two explanations for the presence in infected individuals of many infected cells 
with an identical viral sequence.  Either all of the cells were infected by a predominant 
uniform virus population without mutation or a single cell carrying a particular viral 
sequence proliferated extensively after infection, copying the viral genome without error 
into daughter cells.  The first explanation might apply during acute infection before 
diversification occurs.  However, participants in this study initiated ART during chronic 
infection (Supplementary Table 1) and are thus expected to have extensive viral sequence 
diversity39,40,56.  To demonstrate this diversity, we used single genome amplification of 
DNA from uncultured resting CD4+ T cells to obtain sequences of the env genes of 
proviruses from the same patients.  These sequences were displayed on phylogenetic trees 
together with env sequences from the replication-competent isolates describe above. This 
analysis demonstrated that the replication-competent isolates were part of much more 
complex populations of proviruses in each subject (Fig. 5).  Many of these proviruses may 
have defects elsewhere in the genome and thus will not necessarily show a close 
48 
 
phylogenetic relationship to the replication-competent isolates.  Together these results 
show that the isolation of multiple independent clones of replication-competent virus with 
identical sequence is not due to a lack of sequence diversity in these individuals.    
  To examine the possibility that isolates with identical sequence arose from 
infection of many cells by a dominant virus population, we first examined the genetic 
distance between isolates from the same subject (Fig. 6).  This was done using the env 
sequences obtained from viral RNA in the supernatants of all clonal p24+ wells from the 
MS-VOA (Fig. 3).   If within a given subject a substantial fraction of the latent reservoir is 
generated by infection of many cells by a dominant viral species, then sequences close to 
the dominant species should also be present.  Based on the error rate of reverse 
transcriptase55,57, a single a base substitution is expected in 15-30% of cells infected by this 
dominant viral species. Other closely related sequences should be generated as this 
infection spreads, resulting in many sequences close to the dominant sequence. We 
therefore examined the distribution of genetic distances between independent isolates to 
determine whether isolates close in sequence to the dominant viral species were present.  
As is illustrated in Figure 6, the observed distribution of intra-subject genetic distances 
does not support this hypothesis of infection of many cells by a dominant viral species.  
There is in fact a striking paucity of variants close in sequence to the sets of identical 
sequences. 
To further explore the possibility that the high fraction of independent isolates with 
identical sequence results from infection of many cells by a dominant viral species, we 
focused on five subjects (S01, S03, S10, S11, and S12) for whom there was is a single large 
set of identical isolates that was phylogenetically separate from other isolates or sets of 
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isolates from the same subject. We designed a statistical analysis based on coalescent 
theory to explore the possibility that the high degree of sequence identity observed could 
be explained merely by rounds of viral replication in which no mutation occurred. The data 
for the statistical test is the configuration of sets of identical isolates, that is, the number of 
sets of a given size containing identical env sequences (Table 1). For each patient, the 
mutation parameter estimate 𝜃  is chosen to maximize the likelihood of observing the 
configuration according to Ewens’ sampling formula for the coalescent58. This calculation 
provides the nested model likelihood for the statistical test, (i.e., likelihood without clonal 
proliferation).  Clonal proliferation is assumed to alter the isolate set configuration by 
taking one sequence and increasing its multiplicity, by a mechanism otherwise not present 
in the standard coalescent model. To model this behavior, we suppose that the proliferating 
sequence is (one of) the most frequent sequences observed, and that it effectively replaced 
a number of singleton sequences that would have otherwise been observed in the sample. 
To maximize the likelihood, there are now two parameters: the mutation parameter (as in 
the nested model), and the number of sequences that this largest clone effectively replaced. 
We again use Ewens’ sampling formula, but on an isolate set configuration that is modified 
to reverse the effect of this supposed replacement. In other words, the largest clone is 
shrunk, and singleton sequences are added to keep the total sample size the same. The 
mutation parameter estimate 𝜃  and log-likelihood are computed for this modified 
configuration.  A p-value is then obtained using the likelihood ratio test with one degree of 
freedom (Table 1).  The patterns in all five of these subjects significantly violate the 
distribution of isolate sets expected under a standard evolutionary dynamic without 
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proliferation (p=0.0003–0.027).  For all five participants analyzed, the low p-values 
indicate that mutation-free viral replication is an insufficient explanation for the data. 
Two simplifications may make this test too conservative. First, the test supposes 
that only one sequence may have been expanded.  However, multiple sets of identical 
isolates were observed in several subjects.  For example, subjects S02 and S09 both have 
two large sets of identical isolates that could have arisen through clonal proliferation.  
However, the statistical test was not designed to pick up this pattern. Second, by using only 
the allele configuration and not the full sequence data, the test ignores other potential 
evidence for clonal proliferation. Note that the test checks for any mechanism that may 
increase the multiplicity of a sequence. For example, if positive selection prior to 
administration of ART dramatically increased the frequency of a sequence in the latent 
reservoir, it could produce a positive result by this test. In the setting of chronic infection, 
however, archival viral populations are highly diverse and mostly latent, making this sort 
of dramatic selective sweep unlikely. A final important simplification must be mentioned. 
The coalescent, used in this test, models a single contemporaneous sample of an evolving 
population experiencing generational turnover; however, the latent reservoir for HIV-1 is 
an archive populated over time, more closely resembling a longitudinal sample59.   Overall, 
this analysis of the distribution of identical isolates is more consistent with clonal 
expansion of infected cell than with infection of multiple cells be a dominant viral 
population without mutation. 
 
Discussion 
The extremely stable latent reservoir for HIV-1 in resting CD4+ T cells is a major barrier 
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to cure6-9.  There is concern that the reservoir could be maintained or even expanded by the 
cellular proliferation even when viral replication is fully arrested by ART.  Proliferation of 
infected cells could be driven by antigen, cytokines, or effects related to the site of 
integration10,22,23.  Previous sequencing studies have provided evidence for in vivo 
proliferation of infected cells19,20,22-25,41,46,60.  However, a full understanding of the 
importance of clonal expansion requires consideration of three limitations of current 
studies.  First, much of the evidence for clonal expansion comes from studies showing that 
multiple independent sequences from a single patient are identical.  However, in most 
patients on ART, >98% of proviruses are defective42,44,45, and thus without full length 
sequencing10,22,23 or direct demonstration of viral replication25, it must be assumed that the 
identical sequences represent defective virus, particularly since cells carrying defective 
proviruses are less likely to die from viral cytopathic effects or lysis by host effector cells.  
Second, most studies use subgenomic amplicons, and it is possible that sequences identical 
in the regions analyzed differ elsewhere in the genome43.  Most importantly, even complete 
viral sequence identity does not prove clonal expansion; an alternative explanation is 
infection of multiple cells by a dominant viral species.  Integration site analysis provides 
direct evidence for clonal expansion but does not establish replication competence.  
In light of these issues, two recent studies are of particular importance.  Simonetti 
et al. have described an expanded cellular clone carrying replication-competent provirus 
integrated into a unique site in the human genome that could not be precisely mapped24. 
This clone was identified in a patient with a concurrent malignancy that may have driven 
the clonal expansion24.  Lorenzi et al. recent demonstrated that 54% of replication-
competent isolated from four treated patients had env sequences identical to other isolates 
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from the same individual25.  Together, these studies highlight the disturbing possibility that 
in vivo proliferation of infected cells may be a major factor in determining the composition 
and stability of the latent reservoir.  
The data presented here contribute to our understanding of this issue in several ways.      
We directly demonstrate that cells carrying replication-competent HIV-1 can 
proliferate ex vivo without producing infectious virus and then release virus upon 
subsequent stimulation.  Thus, strong mitogenic stimuli do not always reactivate latent 
HIV-1. In light of the short half-life of productively infected cells26,27, this finding helps 
explain how clonal expansion could occur in vivo.  We also demonstrate the presence of a 
large number of latently infected cells carrying identical viral sequences such that cells 
with identical sequences can be routinely captured in a single blood sample from most 
patients. Overall, 57% of the isolates had env sequences identical to other isolates from the 
same patient.  This finding agrees very well with the study of Lorenzi et al.25   We went on 
to show that sequences identical in the env gene were identical throughout the genome.  In 
addition, through two independent approaches we sought evidence that the identical 
sequences arose through infection of multiple cells by a dominant viral species.  Both 
approaches failed to support this alternative hypothesis, leading us to favor the   explanation 
that the identical sequences arose through the in vivo proliferation of latently infected cells.  
Definitive proof will require simultaneous identification of the integration site and 
demonstration of replication-competence for many proviruses from multiple patients, 
something that cannot be readily achieved with current technology.  Nevertheless, the 
studies presented here raise the possibility that a substantial fraction of the latent reservoir 
is generated by cell proliferation which our ex vivo studies show can occur without release 
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of infectious virus. 
Our results have implications for measurement of the latent reservoir.  Although 
PCR-based assays for proviral DNA are widely used, there is a large discrepancy between 
culture- and PCR-based assays of the latent reservoir.   In comparative studies, PCR assays 
for proviral DNA give infected cell frequencies that are ~300 fold higher than frequencies 
measured by the QVOA52.  This is mainly due to the fact that the vast majority of proviruses 
are defective42,44,45.  However, the number of proviruses that appear intact by full length 
sequencing still exceeds the number induced to release infectious virus in the standard 
QVOA by 20-60 fold42,44.  We show here using a multiple stimulation version of the QVOA 
that additional isolates of replication-competent HIV-1 can be obtained after the 2nd, 3rd, 
and 4th additional rounds of T cell activation.  On average, only 60% of the isolates 
ultimately obtained in the MS-VOA grew out after a single stimulation.  Thus, the standard 
QVOA and other assays that rely on a single round of T cell activation to induce latent 
HIV-1 may underestimate the frequency of latently infected cells as previously suggested44.   
It is important to determine what accounts for this difference.  Some proviruses that appear 
intact by full length sequencing may harbor minor missense mutations that decrease 
replication-capacity.  However, when apparently intact proviruses were reconstructed and 
tested for replication in primary CD4+ T lymphoblasts, 6 of 6 proviruses from 4 different 
infected individuals showed replication equivalent to that of NL4-3 and replication-
competent viruses isolated from the same individuals44.  Another possibility is that some 
proviruses are permanently silenced by integration into regions non-permissive for viral 
gene expression61,62, by transcriptional interference63-65, or by epigenetic modifications66-
68. Finally, stochastic features of the Tat transactivation mechanism may prevent induction 
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of all intact proviruses even in the setting of T cell activation69.  Identification of successful 
latency reversing strategies may require a deeper understanding of these issues. 
The possibility that a substantial fraction of the latent reservoir arises by 
proliferation of a smaller number of infected cells presents some obvious challenges to 
HIV-1 cure efforts.  It will be important to determine the factors driving the proliferation.  
In addition, because the total size of the reservoir does not increase over time6,8,9, any 
proliferation must be roughly balanced by cell loss, and it will be important to understand 















Fig. 3.1. Multiple stimulation viral outgrowth assay (MSVOA). (a) A transwell co-culture 
system (Ho et al., 2013) was used to allow separate manipulation of patient CD4+ T cells 
(green) and MOLT4/CCR5 cells (red). Purified resting CD4+ T cells from subjects on ART were 
plated at a limiting dilution for viral outgrowth and stimulated with PHA and irradiated allogeneic 
PBMC (not shown) as previously described (Finzi et al., 1997, Finzi et al., 1999, Siliciano et al., 
2003, Laird et al., 2016). After 24 h, PHA was removed and 106 MOTL4/CCR5 cells were 
added. Outgrowth in this system is equivalent to standard co-cultures (Ho et al., 2013). (b) 
Assay time course. At 8d after the initial PHA stimulation, half the volume from the top and 
bottom chambers of each transwell is transferred to a new set of transwell plates for a 2nd round 
of PHA stimulation. The initial plates are cultured without further stimulation for a total of 21 
days. The restimulated plates are cultured for 8d following the 2nd round of PHA stimulation and 
then split as above to generate a 3rd set of plates, which receive a 3rd round of stimulation. 
Similarly, these plates are split 8d later to generate the 4th set of plates, which receive a 4th 
round of stimulation. A p24 ELISA was performed 21d after each respective round of PHA 
stimulation to quantify viral outgrowth (dashed lines). In this hypothetical example, each round 
of PHA stimulation induced outgrowth from an additional well (black circles). (c) PHA 
stimulation induces uniform proliferation of resting CD4+ T-cells. Immediately prior to the 1st 
PHA stimulation, an aliquot of resting CD4+ T-cells was stained with carboxyfluorescein 
diacetate succinimidyl ester (CFSE). CFSE dilution was quantitated by flow cytometry 7d after 
stimulation to determine the fraction of cells that had proliferated (red histogram). Cells that did 
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not receive PHA stimulation served as controls (blue histograms). Histogram is representative 
of CFSE dilution from 3 subjects. (d) Increase in cell number after each round of stimulation. 
Results for 3 representative subjects are shown. (e) Activation marker expression induced by 
each round of PHA stimulation. Cells were stained with antibodies to CD4 (x-axis) and the 
activation markers CD25, CD69, and HLA-DR (y-axis) 7d after the indicated round of PHA 
stimulation (red dot plots). Cells that did not receive the most recent round of PHA stimulation 
were analyzed in parallel (blue dot plots). Results are shown for subject 10 and are 






Fig. 3.2. Further rounds of T cell activation induce additional proviruses to produce 
replication-competent virus. (a) Fraction of initially seeded wells becoming p24+ after each of 
four consecutive stimulations with PHA. For each subject (n = 12), a total of 64–72 wells were 
initially seeded. The asterisk indicates that cells from subject 1 only received three rounds of 
PHA stimulation. (b) Fraction of total p24+ wells from each subject (n = 12) that were detected 
for each round of PHA stimulation. The denominator is the total number of initially seeded wells. 
(c) Frequency of cells in the culture at the time of stimulation that are induced to produce 
replication-competent virus by the indicated round of stimulation. Frequency in infectious units 
per million (IUPM) cells was determined for each subject (n = 12) from mean cell counts before 
each stimulation and the number of wells turning p24+ after stimulation using a maximum 
likelihood estimation of infected cell frequency (Rosenbloom et al., 2015). (d) Expression of 
TIM-3 before stimulation (black line) and 7 d after the indicated round of stimulation. Results are 
presentative of exhaustion marker analysis in three subjects. (e) Frequency of latently infected 
cells among the initially plated cells from each subject (n = 12) as detected after a single round of 
PHA stimulation and after a total of four consecutive rounds of stimulation. (f) Schematic 
representation of the relative frequency of infected resting CD4+ T cells detected by different 
assays. The VOA result presents the mean frequency detected after a single round of PHA 
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stimulation in cultures from 12 subjects studied here. The MS-VOA result represents the mean 
frequency among the initially plated cells of latently infected cells as detected by a total of four 
consecutive rounds of PHA stimulation. The frequencies of cells with intact (nondefective) 
proviruses and the total frequency of infected cells as measured by PCR with gag primers were 
estimated from the VOA results and the ratios described by Bruner et al. (2016). The true 
frequency of latently infected cells is between the frequency measured in the MS-VOA and the 






Fig. 3.3. Many independent isolates of replication-competent HIV-1 have identical sequences. 
Phylogenetic trees of env sequences of independent isolates of replication-competent virus from 
each subject (n = 12). Sequencing was performed on genomic viral RNA in supernatants of p24+ 
wells. Cultures were established at limit dilution for viral outgrowth. Isolates containing more than 
a single sequence as indicated by double peaks at one or more positions in the chromatograms were 
not further analyzed. Symbols indicate the number of PHA stimulations after which the isolate was 
obtained. Sets of isolates with identical env sequences are boxed. Representative isolates obtained 
after different numbers of stimulations (arrows) from randomly selected sets were subjected to full-






Fig. 3.4. Full-genome analysis of isolates with identical env sequences. (a) Full-genome 
sequences of isolates with identical env sequences. Randomly selected isolates (arrows in Fig. 3) 
belonging to sets of isolates with identical env sequence were subjected to full-length sequencing. 
Sequencing was performed on single HIV-1 genomic RNA molecules present in the supernatants 
of p24+ cultures after reverse transcription and nested PCR amplification performed at limiting 
dilution. Two overlapping half-genome fragments were amplified. To minimize errors, PCR 
products were directly sequenced without cloning. For each isolate, 6–12 limiting 5′ sequences and 
6–12 3′ sequences were obtained. Neighbor joining phylogenetic trees demonstrated that all 
sequences from a given set of isolates with identical env sequences co-clustered. The minimal 
differences (one to four nucleotides) likely reflect mutations expected to arise during the 3-wk 
outgrowth culture. Symbols indicate the PHA stimulation after which the isolates were detected, as 
in Fig. 3. Results are shown for the 5′ half-genome sequences. Similar results were obtained for the 
3′ half-genome sequences. (b) Genetic distance (mean ± SD) between single-genome sequences 
from a single isolate (intra-isolate), between single-genome sequences from different isolates 
belonging to a set of isolates with identical env sequences (intra-set), between single-genome 
sequences from different sets from the same study subject (intra-subject), and between single 
genome sequences from different patients. For each set of two to three isolates from a given subject, 
6–12 sequences were used for intra-isolate and intra-set comparisons. Then, all sequences were 
used for intra-subject and inter-subject comparisons. (c) Phylogenetic tree of full-genome 
consensus sequences. The 6–12 single half-genome sequences from each isolate were condensed 
to half-genome consensus sequences, which were joined to produce full-genome sequences. Set 2 







Fig. 3.5. Isolates with identical sequence are part of more complex proviral populations 
reflecting diversification over time during chronic infection. Limiting dilution analysis of 
proviruses present in resting CD4+ T cells was performed on cells from three representative 
patients from whom sets of identical isolates of replication-competent virus were obtained. The 
V3-V4 region of env was sequenced, and the resulting sequences (open circles) were used in 
phylogenetic analysis along with the replication-competent isolates (closed symbol; shapes reflect 







Fig 3.6. Distribution of genetic distances between isolates of replication-competent virus from 
individual subjects (n = 12) does not support infection of a large number of cells by a dominant 
viral population. Composite histogram showing the distribution of intra-subject genetic distances 
between isolates of replication-competent virus. To account for differing degrees of genetic 
divergence over time in different subjects, distances are normalized by the largest observed intra-
subject distance. Analysis is based on the highly variable V3-V4 region of the env gene obtained 
as described in Fig. 3. The large peak at the origin reflects the zero branch lengths between 






Fig. 3.7. Schematic illustration of a statistical test based on coalescent theory to explore the 
possibility that the high degree of sequence identity observed could be explained merely by 
rounds of viral replication in which no mutation occurred. The left side of the figure represents 
the sample from participant 03 as analyzed by sequencing of the env gene in supernatant HIV-1 
RNA from clonal p24+ wells (see Fig. 3). A total of 31 independent isolates were obtained, 
including one set with eight isolates (dark blue cells), six smaller sets (other colors), and eight 
unique isolates (singletons). The right side imagines a sample of the same size that would have 
been collected had no clonal proliferation occurred. The large clone is reduced to the size that 
maximizes likelihood under a neutral coalescent, and singletons are added to keep the total 
sample the same size. Because reducing the large clone essentially adds a parameter, a likelihood 
ratio test can be done. As shown in Table 1, p-values for all subjects tested in this manner were 





Table 3.1. a Subjects with a single large set of identical isolate were included in the analysis. 
b The nested model (i.e., model without clonal proliferation) uses the isolate set configuration 
observed for each subject. 
c Clonal proliferation alters the configuration of sets of identical isolates by taking one sequence 
and increasing its multiplicity by a mechanism not present in the standard coalescent model. To 
model this behavior, we suppose that the proliferating sequence is the most frequent sequence 
observed and that it effectively replaces several singleton sequences that would have otherwise 
been observed in the sample. To maximize the likelihood, there are now two parameters: the 
mutation parameter (as in the nested model) and the number of sequences that the largest clone 
effectively replaced. We again use Ewens’ sampling formula but on an isolate set configuration 
that is modified to reverse the effect of this supposed replacement. 
d P-value obtained using the likelihood ratio test with one degree of freedom. A value <0.05 
(italicized) indicates that mutation-free viral replication is an insufficient explanation for the data. 
e The largest set of isolates from each subject is shown in bold. 
f For each subject, the mutation parameter estimate θ^ˆ is chosen to maximize the log-likelihood 
of observing the isolate set configuration according to Ewens’ sampling formula for the 
coalescent (Ewens, 1972). The maximum permitted value for θ^ˆ is 100. 
g Log-likelihood. 
h The size of the reduced isolate set that is created to reverse the effect of clonal proliferation is 
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Abstract 
The latent reservoir (LR) for HIV-1 in resting memory CD4+ T-cells harbors integrated, 
replication-competent proviruses that are not actively transcribed while the T-cells remain 
in a resting state. Given that the LR is the major barrier to HIV-1 cure, it is important to 
understand the proliferative process that contributes to the persistence of the LR. Recent 
work has shown that proliferation of infected cells is a major factor in the generation, 
persistence, and stability of the LR, and that latently infected cells that clonally expand in 
vivo can be reactivated in vitro without producing virus. One hypothesis to explain this 
observation is that certain latently infected memory CD4+ subsets may be in a deeper state 
of latency and therefore may be able to proliferate without producing virus. To evaluate 
this possibility, we cultured resting naïve (TN), central memory (TCM), transitional 
memory (TTM), and effector memory (TEM) CD4+ T-cells from 10 HIV patients on 
suppressive ART in a multiple stimulation viral outgrowth assay (MSVOA). Based on the 
frequencies of viral outgrowth and intact proviral copy numbers quantitated by the intact 
proviral DNA assay (IPDA), only 1.6% of intact proviruses across all subsets were induced 
by the MSVOA. Additionally, there was no enrichment of intact proviruses in any specific 
subset and no correlation between inducibility and subset. Furthermore, we observed 
significant plasticity among the canonical memory subset markers in vitro and saw 
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significant patient-to-patient variability in inducibility that complicates the vision for a 
targeted cure approach based on T-cell subsets. 
Introduction  
The major barrier to curing HIV-1 is the latent reservoir,1,26 which is mainly comprised of 
latently infected resting memory CD4+ T-cells that harbor stably integrated replication-
competent proviruses27–31. The latent reservoir in resting CD4+ T cells was first 
demonstrated using a viral outgrowth assay in which virus production was induced in 
latently infected resting CD4+ T cells through T cell activation28,31–34.  The slow decay rate 
of the latent reservoir necessitates lifelong antiretroviral therapy (ART) to prevent viral 
rebound and disease progression26,35. The slow decay reflects normal memory cell turnover 
as well as various forms of cell death following cellular activation and the concomitant 
reversal of HIV-1 latency. This includes death from viral cytopathic effects or immune 
clearance as well as activation-induced cell death14,36–38. The loss of infected cells is largely 
balanced by clonal expansion driven by antigen, homeostatic proliferation, and effects 
possibly related to the site of proviral integration2,3,9–12,16,39–48. Recent studies have 
identified proliferation of infected cells as a mechanism for HIV-1 persistence9–12.  
Multiple mechanisms may account for proliferation of latently infected cells including: 
cytokine-driven homeostatic proliferation, antigen-driven expansion, and proliferation 
driven by effects related to the site of proviral integration2,3,39–44,46–48. Several groups have 
recently shown that latently infected cells carrying replication-competent proviruses can 
persist through clonal expansion in vivo7,10–12.  
 To purge the reservoir, many groups have looked for cellular markers of latent 
infection49–51 that would allow these infected cells to be targeted for elimination as well as 
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identify specific subpopulations of CD4+ T-cells that may be enriched in cells carrying 
latent, replication-competent proviruses or cells that may differ in propensity for clonal 
expansion or latency reversal8–16. Specific markers of latent infection have not been 
identified57–62 and persistent HIV-1 has been found in several different CD4+ memory 
subsets and at lower levels in naïve CD4+ T cells (TN)5,21,49,52–56.  
 The cell surface proteins CD45, CCR7 and CD27 are commonly used to define 
memory T cell subsets63–65. CD45 is a transmembrane protein of the protein tyrosine 
phosphatase family expressed extracellularly in alternatively spliced isoforms that are 
differentially glycosylated, most importantly CD45RA and CD45RO66. Naïve T-cells 
express CD45RA and upon TCR recognition of a cognate antigen, undergo blast 
transformation and proliferate67. At the conclusion of the immune response, most of these 
activated cells die but some survive and return back to a resting memory state, losing 
CD45RA expression  and upregulating CD45RO expression68–70. Thus, CD45RO is a 
marker of memory CD4+ T cells. CCR7 is a chemokine receptor that mediates lymph node 
homing through interaction with its ligands CCL19 and CCL21, which are highly 
expressed in lymph tissues. CCR7 facilitates homing of cells to secondary lymphoid tissue 
but its expression is lost upon secondary stimulation63. CD27 is a costimulatory TNF-
receptor that binds the ligand CD70, promotes clonal expansion of cells after activation, 
survival of the activated cell through anti-apoptic pathways, and is irreversibly cleaved off 
the surface after antigenic stimulation is removed71. 
 Antigenic stimulation is responsible for the differentiation of naïve CD4+ T-cells 
(TN:CD45RO-CCR7+CD27+) into memory CD4+ T-cells. There are three main subsets of 
memory CD4+ T-cells: central memory (TCM: CD45RO+CCR7+CD27+), transitional 
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memory (TTM: CD45RO+CCR7-CD27+), and effector memory cells (TEM: 
CD45RO+CCR7-CD27-)19,72. TN home to secondary lymphoid organs where they may 
encounter antigen and eventually differentiate into cells with a memory phenotype19,68–
70,72–74,48,50. TCM are long-lived cells whose main function is to mediate a recall response 
to antigen after homing to secondary lymphoid organs39-41,43-46,48-50. TTM are cells 
transitioning from a TCM phenotype to a TEM state43,44,65,75. TEM cells express β integrins 
which allow for homing to inflammatory sites and tissues for rapid effector function by 
producing IFNγ, IL-4, and  IL-543-45,48-50. Based on these functions, CCR7 and CD27 have 
been adopted as canonical surface markers to delineate the different memory subsets.   
There is considerable interest in determining the frequency of latent HIV distribution 
within various CD4+ T cell subsets.  Early studies demonstrated higher frequencies of HIV-
1 in  memory CD4+ T cells than in naïve CD4+ T cells28,77, consistent with models of 
reservoir formation28,78. Subsequent studies have provided conflicting regarding the levels 
of proviral DNA in various CD4+ T cells subsets including TCM, TTM, and TEM52–54 as 
well as Th1 cells79,80, T follicular helper cells (TfH)81, and stem cell-like memory cells 
(TSCM)21,55. Persistence of latent proviruses is clearly influenced by the dynamics of the 
T cell subsets that harbor latent HIV.  Several studies have shown that TCM (and TTM in 
some studies) harbor the majority of latent HIV-1 proviruses, consistent with the 
observation that TCM have the longest half-life of the memory subsets 20,24,52,54,67,82–85.  
However, another study has suggested that TEM harbor latent HIV-1 at higher frequency86.  
One factor that may contribute to differences observed by different groups is the assay used 
to measure the frequency of infected cells in the subsets. There are several different 
methods to quantify different types of HIV-1 in host cells87. The standard QVOA, used for 
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measuring the frequency of replication-competent virus induced to outgrowth in culture, is 
an underestimate of LR size due to noninducible intact proviruses7,28,32–34. HIV-1 DNA 
measurements using qPCR are a large overestimate of LR size since they do not 
discriminate between intact and defective proviruses88,89. Near-full-length sequencing 
(NFLS) is a better estimate of LR size as it can distinguish between intact and defective 
proviruses but is extremely laborious 86,90,91. The ddPCR-based IPDA, recently developed 
in our lab, can distinguish between intact, defective/hypermutated provirus, can sample 
more proviruses than NFLS, and is significantly less labor intensive92. In studies where 
HIV-1 was quantified in different subsets, different methods were used by each group, 
mainly the QVOA, qPCR, or NFLS. These methodical differences may account for some 
of the discrepancies between subset distributions observed for the above reasons. 
In addition to the amount of latent HIV-1 present within T cell subsets, it is important to 
understand the relative inducibility of proviruses in different subsets. Several groups have 
reported differences across memory subsets in regard to permissibility of HIV-1 infection 
depending on coreceptor usage and CCR7 expression93–96, accessibility of chromatin 
modifiers to genes involved in subset differentiation97–99, and cytokine 
responsiveness52,73,74. TNs are more susceptible to infection by CXCR4-tropic viruses, and 
memory cells (especially EMs) are more susceptible to infection by CCR5-trophic 
viruses93,95 in vitro. Furthermore, the presence of the CCR7 ligands CCL19 and CCL21 
increases susceptibility of TNs and TCMs to infection94,96. In regard to epigenetic 
differences, some groups have shown that inducible transcription-related genes are more 
poised (in an open chromatin state with no active transcription occurring) in resting 
memory cells than in naïve cells97,99 and DNA methylation decreases within 
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differentiation-controlling genes as naïve cells differentiate98. Possibly because of the 
poised nature of these transcription-related genes, several groups have shown that EMs 
display a higher proliferative response to IL-7 and IL-15 than less differentiated memory 
subsets52,73,74,100. 
 Initial evidence for differential inducibility of latent HIV-1 proviruses came from a 
multiple stimulation viral outgrowth assay (MSVOA) which was developed to study 
proviruses that were not induced by a single round of T cell activation. 60% of all 
replication-competent proviruses assayed required multiple rounds of T-cell activation to 
reactivate latent virus.  One hypothesis to explain this observation is that proviral 
inducibility is dependent on the subset of memory CD4+ T-cell harboring the latent virus. 
Cells that produce virus after multiple rather than a single stimulation may have required 
additional reactivations to differentiate into an effector memory phenotype with a 
transcriptional landscape that facilitates proviral transcription and expression. To 
determine whether the memory subset phenotype of cells harboring replication-competent 
provirus is indicative of proviral inducibility, we performed the MSVOA on sorted resting 
CD4+ T cells from the TN, TCM, TTM, and TEM subsets from patients on suppressive 
antiretroviral therapy (ART). We analyzed virus from viral outgrowth in culture, quantified 
intact and defective HIV DNA using the IPDA92, and sequenced induced replication-
competent viruses to look for correlations between memory subset, proviral enrichment, 
and viral inducibility. The results provide novel insight on the inducibility of latent 





Study Subjects.. Leukopaks were obtained from 10 HIV+ patients. Study subjects were 
from the UCSF SCOPE cohort who met the inclusion criteria of HIV+ adults who had 
chronic ART-suppression of viremia <20 copies/ml and CD4 count > 400. This study was 
approved by the Institutional Review Board at the University of California San Francisco. 
Written informed consent was obtained from all participants.  
Resting CD4+ T-cell isolation and subset sorting. Peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll density centrifugation. CD4+ cells were isolated from 
PBMCs using the negative depletion EasySep™ Human CD4+ T-cell Isolation Kit 
(Stemcell Technologies). Resting CD4+ cells were then isolated by negative depletion of 
cells expressing CD69, CD25, or HLA-DR (CD69 MicroBead Kit II, CD25 MicroBeads, 
Anti-HLA-DR MicroBeads; Miltenyi Biotec). Cells were stained with CD27-BV421, 
CD3-BV510, CCR7-PE, CD45RO-APC, CD4-PECY7 (Biolegend). Stained cells were 
sorted on the MoFlo Legacy at the Johns Hopkins School of Public Health Flow Cytometry 
and Cell Sorting Core Facility. Viability was determined using a propidium iodide stain. 
Cells were sorted based on the following expression combinations from gated live singlet 
CD3+CD4+ lymphocytes: CD45RO-/CCR7+ /CD27+ (TN), CD45RO+/CCR7+/CD27+ 
(TCM), CD45RO+/CCR7-/CD27+ (TTM), CD45RO+/CCR7-/CD27- (TEM).  
IPDA. Digital droplet PCR was performed on resting subset cells after sorting as previously 
described in the intact proviral DNA assay92. Multiplex ddPCR was performed on the 
QX200 Droplet Digital PCR System (BioRad) using primers and probes that distinguish 
between 5’-deleted, 3’deleted and hypermutated, and intact proviruses.  
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MSVOA. Each sorted subset was cultured in separate transwell plates, where 2x105 sorted 
cells were plated into each top well. The MSVOA was set up as previously described12, 
with irradiated allogeneic PBMCs and phytohemagglutinin added to the top wells to 
stimulate the sorted subset cells, and MOLT-4 cells in the bottom wells to perpetuate 
outgrown virus. The irradiated PBMCs were stained with CellTrace Violet to distinguish 
patient cells from feeders in downstream flow cytometry analysis. The cultures involved 4 
rounds of global T-cell activation every 9 days, then readout by p24 ELISA (Perkin Elmer) 
21 days after each stimulation. 
Flow cytometry. Cells from each subset were stained with Live/Dead Fixable Violet Dead 
Cell Stain Kit (Invitrogen), CD3-BV510, CCR7-PE, CD45RO-APC, CD4-PECy7, and 
CD27-BV785 (Biolegend). Activation levels were determined using CD25-APCCy7, 
CD69-APCCy7, and HLA-DR-APCCy7 (Biolegend). CFSE (Invitrogen) staining was 
done separately on different wells to prevent spillover. Stained and washed cells were 
analyzed on the iQue Screener Plus (Intellicyt) at 4d, 9d, 14d, and 21d for each subset and 
each stimulated group. Data was analyzed on FlowJo.  
Viral RNA sequencing. Culture supernatants were saved after 21d for each stimulation 
group for viral RNA isolation from supernatant. cDNA was synthesized from the isolated 
RNA using the SuperScript IV First-Strand Synthesis System (Thermo Fisher Scientific) 
and gene-specific primer ES8. The V3-V4 region of env was amplified using primers ES7 
(5′-CTG TTA AAT GGC AGT CTA GC-3′), ES8 (5′-CAC TTC TCC AAT TGT CCC 
TCA-3′), and Platinum SuperFi DNA Polymerase (Invitrogen). PCR products were run on 
a 1% agarose gel, extracted (Qiagen QIAquick Gel Extraction Kit), then submitted for 
Sanger sequencing to Genewiz using sequencing primers Nesty8 (5′-CAT ACA TTG CTT 
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TTC CTA CT-3′) and DLoop (5′-GTC TAG CAG AAG AAG AGG-3′). Sequences were 
analyzed in BioEdit, aligned by ClustalW, trimmed to equal lengths, then used to generate 
neighbor-joining trees in MEGA6.  
Results  
Intact proviruses are similar distributed across memory subsets 
To understand the distribution and inducibility of latent HIV-1 proviruses in different T 
cell subsets, we developed a subset isolation method that focuses on the resting CD4+ T 
cells that represent a stable reservoir for HIV-1 in vivo.  CD4+ T-cells were isolated from 
patient PBMCs, and then resting CD4+ T-cells were purified by negative depletion of CD25, 
CD69, and HLA-DR-expressing cells in order to obtain latently infected cells that were not 
actively transcribing integrated proviruses. Resting CD4+ T cells were then stained for the 
subset-defining surface markers (CD27, CCR7, and CD45RO) and also for CD3 and CD4. 
The stained resting CD4+ T-cells were then sorted using the gating strategy shown in Figure 
1a.  Because the subset markers change upon T cell activation (see below), this cell 
purification process ensures that the cells analyzed will accurately reflect the distribution 
of latent HIV-1 in vivo. A fraction of the sorted resting cells was saved for IPDA analysis 
while the remainder of cells were cultured in the MSVOA as shown in Fig. 1b.   
 The IPDA was used to quantitate intact and defective proviruses from genomic 
DNA isolated from sorted resting CD4+ T-cell subsets from 10 patients. The housekeeping 
gene RPP30 was used as a control to correct for shearing that may have occurred during 
DNA preparation and as an internal control for cell equivalents. The number of intact, 5’-
deleted and 3’deleted/hypermutated proviral copies per 106 cell equivalents were 
calculated for each subset within each patient. Naïve cells contained nearly 10-fold fewer 
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proviral copies (both intact and defective) than memory cells (Fig. 2a). The mean copy 
numbers of intact proviruses per 106 cells were similar across the subsets (527, 475, 800 
for TCM, TTM, and TEM, respectively), suggesting there is no enrichment of intact 
proviruses in any particular subset (Fig. 2a). To confirm the lack of intact provirus 
enrichment across subsets, we performed paired t-tests comparing each subset and 
observed no significant difference among the different subsets (p>0.17). Similar mean 
copy numbers of 5’ and 3’ deleted proviruses were also found across the subsets for all 
patients (Fig. 2a).   
 To determine the contribution of each subset to the total pool of intact proviruses 
found in each patient, we calculated the frequency of each subset in peripheral blood (Fig 
2b). The relative frequencies of each subset were as expected, with TN being the most 
abundant, followed by CM, EM, and TM. The contribution of each subset to the pool of 
intact proviral DNA copies for each patient was then calculated by considering both the 
intact copy values per 106 cells and the frequency of each subset. After normalization, we 
observed a wide distribution of intact proviruses across the subsets (Fig. 2c). Overall, no 
particular subset consistently contributed most to the total pool of intact proviruses. In 
different patients, different subsets made the largest contribution to the total population of 
intact proviruses. 
 
Subsets differentiate toward effector phenotype in MSVOA  
In order to understand the apparent lack of a relationship between conventional CD4+ T 
cell subsets and the distribution of intact proviruses, we examined changes in expression 
of markers used to define the subsets upon T cell activation. Following sorting, 4.8x106 
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cells of each subset (resting CD4+ TN, TCM, TTM, and TEM) were seeded into the 
MSVOA at 2x105 cells/well in a transwell system as previously described12.  This system 
allows for repetitive stimulation of cells in wells that are initially negative for viral 
outgrowth. Cells were then activated with the mitogen phytohemagglutinin (PHA) and 
irradiated allogeneic PBMCs for twenty-four hours, then co-cultured with MOLT-4 cells 
to expand induced replication competent virus (Fig. 1b). Cultures were split every 9 days 
at which time half of each culture was restimulated while the remaining half of the cells 
were cultured without further stimulation for 21 days. At 21 days after the last stimulation, 
p24 antigen was measured in the supernatant to detect viral outgrowth, and viral RNA from 
culture supernatants was saved for sequencing.  
 We measured markers of activation and proliferative activity at different time 
points throughout the course of the experiment. Regardless of the number of stimulations 
received, cells remained at least 70% activated throughout the duration of the culture, as 
determined by CD25 and CD69 expression (Fig. 3a). CFSE dilution observed in each 
subset after initial seeding and activation demonstrated that all cells proliferated in the 
culture system (Fig. 3b).  
 Phenotypic CD4+ T-cell subset markers were assessed every 5-7 days by flow 
cytometry, including after each stimulation.  Notable changes in phenotype were observed 
throughout the course of these cultures. TN gained CD45RO expression by 4 days after the 
initial activation (Fig. 3c). In Figure 3d, we observed that CCR7 expression on TN and 
TCM remained high after initial activation, then decreased over time as cells approached 
an EM phenotype in culture by day 21. Interestingly, TTM and TEM strongly upregulated 
CCR7 expression after initial activation from their CCR7- state. CD27 expression also 
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showed dramatic changes upon T cell activation, with a more complex pattern that varied 
between individuals and subsets. In TN and TCM, CD27 expression fluctuated and showed 
a variety of phenotypes among patients on day 21 (Fig. 3d). In general, CCR7 and CD27 
expression demonstrated changes consistent with memory subset differentiation from TN 
→ TCM → TTM → TEM with repeated stimulations, as expected and confirmed by a 
previous study of in vitro subset differentiation in non-HIV-infected individuals65,75 (Supp 
Fig. 1). The finding that the markers used to define memory subsets can change 
dramatically upon T cell activation suggests that studies of memory cell subsets should be 
performed on purified resting CD4+ T cells. 
 
Inducibility of provirus expression is not dependent on memory subset  
To test the hypothesis that inducibility of provirus expression varies based on memory 
subset, we performed the MSVOA on each sorted subset and p24 ELISAs 21 days after 
each stimulation in order to determine the amount of outgrowth induced after each 
stimulation. Resting CD4+ TN, TCM, TTM, and TEM were sorted and separately seeded 
into the MSVOA as previously described12 (Fig. 1b). The frequency of cells with 
replication competent virus was determined as previously described (IUPMStats v1.0)101 
based on the initial number of cells seeded at the beginning of the culture. IUPM values 
from cultures that received only one stimulation showed no induction of viral outgrowth 
from TN in most patients while we observed the highest IUPMs in TM and EM (Fig. 4a). 
When these frequencies were normalized to the frequency of each subset found in the 
peripheral blood, we observed similar contributions of each subset to the total pool of 
replication-competent viruses induced after one stimulation (Fig. 4b). To determine the 
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number of intact proviruses that were replication-competent after one stimulation, we 
calculated the ratio of IUPM to intact copies per million cells (ICPM). We observed less 
inducibility in TN due to lower copies of intact provirus quantified in TN; however, in the 
three memory subsets, we observed on average 0.5% of intact proviruses induced by one 
stimulation (Fig. 4c).   
 To test for differential inducibility of the resting CD4+ subsets, we continued our 
cultures in the MSVOA with 4 consecutive rounds of stimulation. As we have previously 
shown12, viral outgrowth after each stimulation varied from patient to patient, with 
additional outgrowth being observed after multiple stimulations for some patients but not 
others (Fig. 5a). Outgrowth from the TN cultures was lower relative to outgrowth from the 
other subsets for all patients, but there were no clear patterns in either outgrowth or the 
number of stimulations required for outgrowth among the 4 subsets studied (Fig. 5b). For 
example, TM cells required multiple stimulations for outgrowth in some patients but only 
one stimulation for maximum outgrowth in other patients, and this trend was seen in other 
subsets (Fig. 5b). IUPM values calculated after four stimulations versus after one 
stimulation were on average 10-fold higher, signifying the robustness of the MSVOA in 
inducing additional viral outgrowth compared to a single round of maximum T cell 
activation (Fig. 5c). To determine if a particular subset contributed more to the total pool 
of replication-competent viruses induced after four stimulations, we looked at IUPM values 
normalized to the frequency of subsets present in peripheral blood as calculated above and 
found that no particular subset has a significant contribution (Fig 5e). The calculated 
inducibility factor only rose slightly to an average of 1.56% induction of all intact 
proviruses four stimulations (Fig. 5f).  
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 In order to understand the lack of a relationship between conventional CD4+ T cell 
subsets and the distribution of replication-competent proviruses, we examined the 
phenotypes of the cells in culture at the timepoints when outgrowth was measured (Fig 5g). 
Some TN only differentiated to TCM or TTM and do not reach TEM phenotype by day 21 
in culture (Fig. 5g, Supp Fig. 1a). This suggests that memory CD4+ T-cells do not prefer 
nor are required to have an effector phenotype to produce virus (Supp Fig. 1b).  
 
Only a small fraction of intact proviruses are induced to replicate despite multiple 
stimulations  
To confirm the lack of correlation between inducibility and subsets, we tested several 
different methods of interpretation. We quantified inducibility by comparing the fold-
changes in IUPM after one or multiple stimulations within each patient, and within each 
subset (Fig. 6b). The lower the fold-change, the higher inducibility due to most outgrowth 
being observed after a single stimulation. We observed varying ranges of IUPM fold-
change across patients; for example, patients 2006, 3147, 2013, and 2274 did not see 
substantial additional outgrowth in any of the subsets compared to the other patients. When 
looking at IUPM fold-change by subset, we did not observe any pattern of inducibility 
within an individual subset. The differences in numbers of stimulations required for 
outgrowth for the different subsets further show that the inducibility of a provirus is not 
dependent on the particular subset of the host cell. 
 To determine the number of intact proviruses that were replication-competent in 
culture, we calculated the ratio of IUPM to ICPM. This inducibility factor was on average 
1.56% across all subsets (Fig 6a). This suggests that only 1.56% of the intact proviruses 
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present in these cells are induced to replicate in culture. The MSVOA is currently the most 
robust method of inducing outgrowth; however, it is only able to induce 1 more log of 
infectious units per million cells compared to the standard QVOA (Fig. 5c), and even then 
can only induce 1.56% of intact proviruses to outgrowth. We also observed no correlation 
between IUPM and ICPM, suggesting that not all intact proviruses are equally inducible 
(Fig. 6c). 
 
Replication-competent viral clones are stochastically distributed across different 
subsets  
The V3-V4 region of env was sequenced from viral RNA from the supernatants of p24+ 
positive culture wells (Fig. 7a). Based on the clonal prediction score calculated for this 
region102, we used sequences from this region to assess clonality of the viruses that 
replicated from each subset. As shown by our group and others, we observed identical 
viruses growing out from different wells at different timepoints, confirming clonal 
expansion of these replication-competent proviruses in vivo. Interestingly, from the 157 
sequences we obtained from the different subsets from 10 patients, we observed identical 
clones that replicated from different subsets after different numbers of stimulations, 
suggesting that the subset phenotype plays no role in preferential infection or differential 
inducibility of proviral expression. To determine if there were any trends in sequence 
variability between subsets, we calculated the genetic distances of each viral sequence from 
each subset to the reference genome hxb2 (Fig 7b). We found no significant differences in 
the sequences from one subset compared to another, in consensus with findings from 
Heeregrave et al103. Overall, we saw no compartmentalization of viruses or clones within 
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a single subset, confirming that there are no distinguishing viral characteristics within 
certain subsets.  
Discussion 
In this study, we looked at the distribution and inducibility of intact, replication-competent 
proviruses in resting CD4+ TN, TCM, TTM, and TEM. Intact proviruses quantified by 
ddPCR were measured in all CD4 + T cell subsets and were unevenly distributed in all 10 
patients. We calculated similar mean ICPMs across the 3 memory subsets. Although we 
observed 10-fold less copies of intact and defective proviral DNA in TNs, 0.01% of TNs 
still contained HIV-1 DNA. Even more compelling, we discovered a measurable number 
of replication-competent virions from TNs that were induced in the MSVOA. However, in 
5/10 patients, we detected no intact proviral DNA in TNs and no viral outgrowth after all 
4 stimulations (Supp Table 2). Normalized to the relative frequencies of each subset present 
in the peripheral blood, there was a wide distribution of each subset’s contribution to the 
total pool of intact proviruses within each patient. This further confirms that there is no 
enrichment of intact proviruses within any particular subset and highlights the patient-to-
patient variability that prevents any generalization about the role of different memory 
subsets in the latent reservoir.  
 Despite not finding enrichment of intact proviruses in any particular CD4+ memory 
T-cell subset, it was possible that there might be differential inducibility of replication-
competent provirus in a particular memory subset. We initially hypothesized that subset-
specific differences in transcriptional and translational activity may result in differential 
inducibility. Characterization of the epigenetic landscapes and cytokine responsiveness of 
each subset suggested that TEMs would be easiest to induce transcription and translation 
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in, followed by TTMs, TCMs, then TNs52,73,74,85,97–99. If so, TCMs would be the most 
difficult subset to induce viral transcription and latency reversal. To test this, we subjected 
sorted subset cells to 4 consecutive rounds of global T-cell activation to experimentally test 
whether TEMs would require the least number of stimulations. However, we found that 
there was no trend or correlation between the number of stimulations needed for viral 
outgrowth and the subset phenotype. Several groups have looked at the inducibility of HIV-
1 in primary cell models, where some groups observed differential inducibility and some 
observed no differences between subsets104. 
 To assess the frequency of intact proviruses that were induced to replicate in the 
MSVOA, we calculated the inducibility factor from the ratio of IUPM to ICPM. On 
average, we observed 1.6% of all intact proviruses were induced to replicate in this in vitro 
culture assay. This value is similar to that seen after a single round of maximum T cell 
stimulation in the standard QVOA (~1%) (ref), despite seeing IUPM values 10-fold higher 
in the MSVOA than QVOA. Fascinatingly, this number is in exact agreement with similar 
inducibility measurements performed by Cillo et al, in which they detected virion-
associated RNA from 1.5% of proviruses in culture using anti-CD3/CD28 antibodies and 
a maximum likelihood estimate to calculate the total number of proviruses (intact and 
defective)105. The alarmingly high 98.44% of intact uninducible proviruses must be further 
investigated to determine how and whether they contribute to the latent reservoir and 
residual viremia. Of many possibilities, they a) may either have small defects not detected 
by the IPDA that render them replication-incompetent, b) may be permanently silenced 
thus never transcribed or translated, c) may in fact be replication-competent in vivo but not 
able to be induced in vitro by global T-cell activating methods, or d) may also be integrated 
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in a genetic location that affects inducibility. However, if a large proportion of these are 
eventually inducible and replication-competent but were not inducible in vitro, it implies 
an enormous hurdle to eradicating the reservoir. Therefore, further investigation will be 
needed to characterize these intact proviruses.  
 This study also highlights the importance of distinguishing resting vs activated 
CD4+ T-cells when sorting memory subsets based on the canonical subset surface markers. 
As expected, we induced differentiation of the subset cells in culture after activating them 
with PHA. However, TMs and EMs, which are characterized as CCR7-, demonstrated 
CCR7 expression a few days after activation before downregulating CCR7. Figure 8 
highlights the differences in surface marker expression in resting vs activated states. 
Activated TMs have the surface phenotype of a CM, and activated EMs have a 
CCR7+CD27- phenotype, which would exclude them from being sorted as CCR7-CD27- 
EMs. The plasticity of these surface markers is important to consider when performing a 
surface marker-based sort of the memory subsets. Functional characteristics of these cells 
based on cytokine production or transcription factor activity may more accurately reflect 
the specific subsets106. In this study, we did not observe any enrichment or differential 
inducibility of latent intact proviruses in any particular subset of memory CD4+ T-cells.  
This suggests that targeting a particular subset may not significantly reduce the latent 
reservoir. It is not possible to know the exact memory phenotype of the cell at the time of 
infection in vivo; based on our env sequences, 95% of the viruses were predicted R5-
tropic107 but most were from largely expanded clones. Some groups have looked at the 
different levels of susceptibility of each subset to infection but this is independent of the 
differentiation timeline of the cell93,103,108.  
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 Recently, many cure strategies involve identifying markers of latently infected cells 
which would allow this population to be selectively targeted. Overall, our results 
demonstrate that a specific memory CD4+ T-cell subset cannot be targeted, as latent 
replication-competent proviruses seem evenly distributed among the memory subsets with 







Fig. 4.1. Subset sorting strategy and MSVOA culture schematic. (a) Resting CD4+ T-cells were 
isolated from leukopaks from 10 patients on ART, stained for CD3, CD4, CD45RO, CCR7, and 
CD27. Cells were sorted by lymphocytes, singlets, live cells (based on propidium iodide stain), 
CD3+ CD4+, and then TN (CD45RO- CCR7+ CD27+), TCM (CD45RO+ CCR7+ CD27+), TTM 
(CD45RO+ CCR7- CD27+), and TEM (CD45RO+ CCR7- CD27-). Sorted cell numbers were used 
to calculate frequency of each subset present in peripheral blood in Fig. 2b. (b) A small aliquot of 
the sorted resting cells were set aside for IPDA analysis and calculations of intact and defective 
proviruses (Fig. 2a). Of the remainder, 2x105 cells from each subset were seeded into separate 
plates in a transwell system, with irradiated allogeneic PBMCs and subset cells in the top chamber 
and MOLT-4 cells in the bottom chamber. Cells were activated with PHA on day 0, then cultures 
were split in half on day 9, with half remaining incubated until day 21 for p24 ELISA (outgrowth 
data in Fig. 4) and the other half activated again with PHA. This was repeated for a total of 4 PHA 
stimulations every 9 days, and p24 data are shown in Fig. 5. Flow cytometry was run every 5-7 






Fig. 4.2. Frequencies of subsets in periphery and proviral DNA copies. (a) IPDA data from 
resting cells of each subset. There are always ~10-fold more defective (5’ half deleted, 3’ half 
deleted, hypermutated) copies than intact in any patient sample. Less naïve cells harbor proviruses, 
but on average, each memory subset contains roughly equivalent numbers (mean=600) of intact 
proviral copies per million cells. For some subsets in some patients, the frequency of intact 
proviruses was below the limit of detection (noted by open circles). Paired t-tests were performed 
to compare ICPM within each subset to each other to show that there is no significant difference in 
the ICPM of each subset. (b) Frequency of each subset sorted from a single leukapheresis 
(mean±SD). Naïve CD4+ T-cells are the most prevalent, followed by central memory, then 
transitional and effector memory cells with mean frequencies less than 12%. (c) Percent of intact 
proviruses found in each subset (b) normalized to frequency of subset in peripheral blood (a). 
Contribution of each subset to the total pool of intact proviruses varies from patient to patient with 
no apparent enrichment within any particular subset. Paired t-tests between subsets showed no 






Fig. 4.3. Cell culture maintenance and phenotype marker kinetics. (a) Activation status of 
CD4+ T cells throughout the MSVOA averaged across 4 representative patients. Arrows denote 
stimulation times. Graph shows percent of cells co-expressing CD25 and CD69.  (b) CFSE 
proliferation of cells in MSVOA after first stimulation. Cells from each subset were stained with 
CFSE and activated on day 0, then analyzed by flow cytometry at days 4 and 9 to verify 
proliferation of each subset. (c) CD45RO expression of naïve cells from representative patient. Red 
histogram represents CD45RO+ patient cells, gray represents negative control. Of naïve cells that 
were originally CD45RO- at time of sort (Supp. Fig. 1a), 91.6% of cells became CD45RO+ by day 
4 after initial stimulation. (d) Percent of subset cells in culture expressing CCR7 and CD27 at given 
timepoints. Arrows denote times of additional stimulation. CCR7 expression decreases over time 
as cells differentiate in culture. In TM and EM, where CCR7 is not normally expressed, activation 
led to upregulation of CCR7, then downregulation over time. Cultures were activated at days 0, 9, 
18, and 27 as denoted by arrows. CD27 expression generally decreases over time in culture in 
subsets except for naïve cells, in which they maintain surface expression in most patients. All TM 
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Fig. 4.4. P24 results and outgrowth observed after one stimulation as in traditional QVOA. 
(a) IUPM calculated after one stimulation. (b) Contribution of subsets to total pool of replication-
competent proviruses induced after one stimulation. (c) Percentage of intact proviruses that were 
induced to replicate after one stimulation.  
  






































Fig. 4.5. P24 results and additional outgrowth observed after four stimulations in MSVOA. 
(a) Fractions of all wells that became p24+ after each stimulation for individual patients. (b) 
Fractions of all p24+ culture wells after each stimulation for each subset. (c) Infectious units per 
million subset cells calculated based on initial number of cells seeded and number of wells turned 



























































































































































































There seems to be no pattern in inducibility of virus in each subset. (d) IUPM calculated from 
total numbers of wells that became p24+ throughout MSVOA based on initial number of cells 
seeded. (e) Contribution of each subset to total pool of replication-competent proviruses (IUPM) 
based on frequency of subset present in peripheral blood (Fig. 2b). (f) Inducibility factor 
calculated from ratio of MSVOA IUPM to ICPM from each subset. (g) Phenotype of cultured 
cells overlaid with outgrowth data for each subset for one representative patient. Left y-axis 
shows levels of CCR7 and CD27 expression at each timepoint to represent phenotype. Right y-






Fig. 4.6. Inducibility of viruses from different subsets. (a) Range of inducibility factors among 
subsets (mean and SD shown). On average, only 1.56% of intact proviruses measured were induced 
to replicate in culture. Paired t-tests showed no significant difference in means of inducibility 
factors across subsets (p>0.24). (b) Fold-change in IUPM by patient and by subset. There is patient-
to-patient variability seen in inducibility across all subsets. For example, patient 3147 did not 
require additional stimulations for additional outgrowth from any of the subsets, whereas patient 
2461 required multiple stimulations for additional outgrowth from all subsets tested. (c) Spearman 





Fig. 4.7. Neighbor-joining env trees of outgrown viruses from subsets. (a) env sequencing of 
outgrown viruses from 4 different timepoints (21d after each stimulation) from culture supernatants. 
Clonal viruses from different subsets show that cells carrying these clonal proviruses can 
differentiate separately from each other, further showing that subset phenotype is not a predictor of 
inducibility. (b) Genetic distances of sequences from each subset were calculated relative to the 
reference genome hxb2. No significant genetic differences were seen in viral sequences between 

















































Fig. 4.8. Illustration of surface marker differences on resting vs activated CD4+ subsets. After 
activation with PHA, expression of the canonical subset-distinguishing surface markers changes. 
Naïve cells begin expressing CD45RO as they differentiate into memory cells. TMs and EMs, 
which are CCR7-, start expressing CCR7 after activation. In culture after activation, the initially 
resting subset cells differentiate toward the effector memory phenotype (CCR7-CD27-). This 
highlights the importance of distinguishing resting vs total CD4+ T-cells which include activated 
cells. For example, the activated TM cell exhibits the same surface markers as the activated CM 
cell; even if they may not be functionally similar, they would be sorted into the same population 
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